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The goal of my PhD thesis research was to identify new potent and specific 
inhibitors of untargeted proteins that can be used as tools to study biology and serve as 
starting points for the development of new drugs down the road. I decided to focus on a 
recently discovered antitumor natural product known as agelastatin A (AglA), derived 
from the marine sponge Agelas dendromorpha. Using a systematic approach, I show 
that AglA selectively inhibits protein synthesis. Protein synthesis plays an essential role 
in cell growth and survival, especially in fast-proliferating cancer cells. Several inhibitors 
of eukaryotic protein synthesis have entered the clinical stage, establishing translation 
as a promising target for chemotherapy. 
I have verified the inhibition of translation elongation by [35S]-methionine labeling 
experiments, an in vitro HCV IRES dual luciferase assay, and a stress granule formation 
assay. AglA was found to act at an early stage of translation elongation, inhibiting 
dipeptide bond formation. Based on these findings, we predicted that AglA disrupts 
peptide bond formation by binding to the peptidyl transfer center (PTC) of the ribosome. 
Using a new chemical footprinting method, we initially identified the AglA to ribosomal A-
site proximal to the C2821 25S rRNA residue in the 60S ribosomal subunit. X-ray 
crystallography was used to determine a high-resolution structure of 80S ribosomes 
from Saccharomyces cerevisiae in complexes with AglA, which validated the binding site 
originally determined by chemical footprinting. Not only is this promising for the 
discovery of new cancer therapeutics; perturbation of translation by AglA will provide 
further mechanistic insight into the eukaryotic ribosome and its components. In the 
future, we hope that these insights will establish further contrasts between prokaryotic 
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Chapter 1. Introduction 
This thesis interpolates material from a paper by the author. Chapter 2 uses 
material from Jouanneau et al., 2016. Chapter 3 uses material from an unpublished 
manuscript. Some material from each of these sources has been incorporated into this 
introductory chapter. 
Defined broadly, natural products are chemical compounds produced by 
biological sources including plants, animals, and microorganisms. Due to their biological 
activity, many natural products serve as the active components of traditional medicines 
and offer therapeutic benefit in treating diseases, particularly in cancer and microbial 
infection (Koehn and Carter, 2005). Historically, many drugs and bioactive small 
molecules, particularly natural products, were discovered based on their ability to exert 
pharmacological effects at the cellular or whole organismal level. Currently, the targets 
of many widely used drugs and bioactive natural products have been identified, leading 
to a deeper understanding of the physiological functions of the newly identified protein 
targets and opening gateways to the subsequent studies of the corresponding cellular 
processes.  
In attempts to obtain new chemically diverse compounds that will be analyzed 
and evaluated in drug discovery bioassay screens, researchers travel around the world 
to biologically diverse environments and collect samples of microorganisms or plants. A 
crude extract from any one of these natural sources typically contains a range of 
structurally diverse and often novel chemical compounds with biological activity. 
Following isolation, purification, and identification through determination of the chemical 
structures, the active compounds can evolve to become discovery "leads." Indeed, some 
current medicines have been developed directly from those leads.  
The approach of producing immense numbers of synthetic compounds by 
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combinatorial chemistry has largely failed in offering sufficient candidate compounds for 
developing new drugs (Ortholand and Ganesan, 2004) . The difficulties with these large 
synthetic libraries may also reflect on another advantage of molecules derived from 
natural sources: production of secondary metabolites requires a significant investment of 
energy and resources for the organism, but this investment becomes worthwhile when it 
creates a selective benefit to the host organism. For this very reason, natural product 
collections are essentially evolutionarily pre-screened, enhancing the likelihood of finding 
interesting compounds. This has an advantage in that they are novel compounds, but 
the chemical complexity also makes the synthesis of such compounds difficult. Instead, 
the compound may need to be extracted from its natural source, which can many times 
be a labor intensive, expensive and inefficient process. As a result, there is an 
advantage in designing simpler analogues. Fortunately, with the emergence of molecular 
technology, it is now possible to isolate the biosynthetic machinery responsible for 
natural product production. Furthermore, some synthetic analogs of natural products 
with improved potency and safety can be prepared through total/semisynthesis. This 
allows natural products to successfully serve as starting points for drug discovery 
(Beghyn et al., 2008; Hunter, 2008; Koehn and Carter, 2005), although, as discussed in 
Chapter 2, slight alterations of structures of natural products can also drastically alter 
their mechanisms and effects.  
 
Agelastatin A 
The majority of the current natural product-derived therapeutics has terrestrial 
origins. However, mining novel sources, such as the marine environment, is clearing the 
way for chemical and biological novelties as well. Recently, marine natural products 
have served as valuable sources for novel drugs (Montaser and Luesch, 2011). This 
project began with acquisition of marine natural products from the laboratory of Dr. 
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Daniel Romo at the Texas A & M, currently at Baylor University. One recently discovered 
antitumor natural product is the structurally unique brominated alkaloid Agelastatin A 
(AglA). Isolated from the marine sponge Agelas dendromorpha in 1993 from the coast of 
the Coral Sea, AglA belongs to the pyrrole-2-aminoimidazole alkaloid (PAI) family 
(D’Ambrosio et al., 1993).  Since then, many efforts toward total synthesis of this natural 
product have been made (Dong, 2010a; Jouanneau et al., 2016; Reyes and Romo, 
2012). AglA has shown potent activity against several human cancer cell lines (Han et 
al., 2013; Jouanneau et al., 2016; Stout et al., 2014). More recently, AglA and its 
analogues have displayed excellent blood-brain barrier penetration,  making it an 
excellent candidate for brain cancer studies (Li et al., 2013).  Previous reports identified 
AglA as an inhibitor of β-catenin, osteopontin-mediated malignant transformation, and 
glycogen synthase kinase-3β (Mason et al., 2008; Meijer et al., 2000). However, it 
remains unclear whether this inhibition is responsible for its underlying antiproliferative 
activity.  
 
Target Identification of bioactive molecules 
To identify the primary target of AglA, we took advantage of the two general 
target identification methods: the bottom-up and top-down approaches. The bottom-up 
approach, a target based approach, consists of methods that allow for the direct 
identification of a protein target using genetics or affinity based methods. We call this the 
"bottom-up" approach because the identification of a target protein serves as an initial 
base before building up to explain the phenotype through perturbation of the function of 
the target protein (Titov and Liu, 2012). 
The top-down or phenotypic approach consists of methods that allow 
identification of the protein target by exploiting the existing knowledge of a given cellular 
process that is perturbed by a small molecule. We call this the “top-down” approach 
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because it allows one to systematically narrow down the possible targets based on a 
general understanding of cellular pathways that the small molecule perturbs, and the 
proteins known to be involved in the relevant processes (Titov and Liu, 2012).  
This thesis will cover efforts to identify the primary target(s) of AglA using both 



















Chapter 2. Derivatization of agelastatin A leading to 






()-Agelastatin A (1, AglA) is a tetracyclic member of the pyrrole-2-
aminoimidazole alkaloid (PAI) family (Al-Mourabit et al., 2011; Forte et al., 2009). Since 
its isolation in 1993 by Pietra and co-workers from the sponge Agelas dendromorpha 
(D’Ambrosio et al., 1993; Guerriero et al., 1994),  this family has grown to include six 
agelastatin congeners (A through F, Fig. 1a)(Hong et al., 1998; Tilvi et al., 2010). 
Weinreb (Stien et al., 1999) described the first total synthesis of AglA and since then 
several additional racemic (Domostoj et al., 2004; Duspara and Batey, 2013)  and 
enantioselective (Movassaghi et al., 2010; Wehn and Du Bois, 2009) syntheses of AglA 
have been reported (Al-Mourabit et al., 2011; Dong, 2010b). Recently, Movassaghi 
developed an elegant and efficient bioinspired approach to AglA and all congeners that 
involved a late stage C4–C8 bond formation (Movassaghi et al., 2010). Our collaborator, 
Dr. Romo’s group reported an alternative bioinspired approach that involved a final 
Npyrrole–C7 bond formation (Reyes and Romo, 2012). The reported bioactivities of this 
alkaloid are varied and include inhibition of -catenin (Mason et al., 2008), suppression 
of osteopontin-mediated malignant transformation and inhibition of glycogen synthase 
kinase (Meijer et al., 2000). AglA and derivatives demonstrated good potency against 60 
leukemia (Stout et al., 2014)  and notably displayed excellent blood–brain barrier 
penetration (Li et al., 2013). These recent studies by Molinski and Yoshimitsu revealed 
that substitutions at C13 on the pyrrole ring are tolerated (Fig. 1c) with addition of a C13-
trifluoromethyl and chloro substituent providing a marked increase in potency toward a 
leukemia and a breast cancer cell line, respectively. While AglA has been an attractive 
target for both synthetic and biological studies over two decades, a molecular level 
understanding of its effects in cells including cellular target(s) has not been described. 
Herein, we report expanded structure-activity relationship studies of agelastatin A 
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enabling the identification of an active chloro derivative and the design and synthesis of 






Synthesis of agelastatin A analogs  
Our derivatization of AglA focused on functionalization at C14 and C15 of the 
pyrrole ring given the lack or absence of investigations of these positions. Given the 
efficiency and scalability of the Movassaghi synthesis of all known agelastatins, we 
prepared ()-agelastatin A (1) for our studies as described starting from D-aspartic acid 
in 9 steps in ~4% overall yield (95% ee) and all derivatives prepared herein began with 
this material (Movassaghi et al., 2010).  Iodination with N-iodosuccinimide (NIS) 
promoted by (InOTf)3 (Zhou et al., 2010) gave 14-iodo 2 in 74% yield (Scheme 1) which 
Fig. 1.  (a) Agelastatin A (1) and congeners. (b) Structure–activity relationship 





enabled subsequent functionalization of C14 through chemoselective Pd-mediated 
reactions.  
 
Initial chlorination conditions employing standard conditions (NCS) gave complex 
mixtures, however chlorination of AglA with Palau’chlor® (Rodriguez et al., 2014) gave a 
mixture of the desired 14-chloro AglA 3 (24%) and AgelB 4 (30%) along with traces of 
C13,C14-dichlorinated derivative detected by LCMS. Modified reaction conditions 
allowed access to AgelB  in 5 min using KBr and selectfluor®, as brominating agent 
Scheme 1. Synthesis of halogenated AglA derivatives 2–6 by the Romo group. 
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Scheme 2. Synthesis of methylated pyrrole AglA derivatives 
(Syvret et al., 2002; Ye and Shreeve, 2004). Longer reaction times (1 h) with excess 
brominating agent gave AgelB (4) with 15-bromoAgelB (5) in 46% yield, the first C15 
functionalized AglA derivative. The 15-iodoAgelB (6) was synthesized from AgelB (4) 
employing a large excess of iodine in the presence of Lewis acid (Zhou et al., 2010) in 
71% yield over extended periods (2 days). Alternatively, treatment of AglA with 1.5 
equivalent of NBS followed by iodine at 60 °C for 16 h gave iodo derivative 6 in 60% 
yield.  
With various halogenated pyrrole derivatives in hand, we studied methylation of 
the pyrrole ring to differentiate steric versus electronic effects in this heterocycle 
beginning with C15. Methylation at C15 was studied through both Stille and Suzuki 
conditions 100 (Scheme 2). Under Suzuki conditions, a mixture of the mono and 
dimethylated compounds 7, 8 was obtained in favor of the dimethyl derivative. Stille 
conditions delivered only the monomethyl derivative 7 in 77% yield. Hydrogenolysis of 







Further substitutions on the pyrrole ring were investigated including arylation, 
alkynylation and acylation (Scheme 3). Suzuki coupling with phenylboronic acid gave a 
mixture of bis- and mono-arylation products providing 13,14-diphenyl derivative 10 and 
14-phenyl derivative 11 derivatives in 23% and 19% yields, respectively. Stille coupling 
with tetramethyltin and tributylethynylphenyltin gave the 14-methyl derivative 12 and 14-
ethynylphenyl derivative 14 in 26% and 55% yield, respectively. Stille coupling with an 
enol ether stannane followed by mild hydrolysis gave the C-acetylated derivative 13 in 






















Scheme 4. Synthesis of O-substituted, N9 and aminal AglA derivatives 15, 17–19 
Modifications of the C5 and N9 positions were also studied leading to several O- 
and N-substituted derivatives and a stable aminal derivative. Triazole amide derivative 
15 was obtained via acid catalyzed C5 substitution with 4-pentyn-1-ol followed by 
Sharpless-Hüisgen cycloaddition with α-azido-N-benzylamide (A) to provide amide 15 in 
46% (Scheme 4). Inspired by Pietra’s work (D’Ambrosio et al., 1993), acetylation of the 
C5 carbinolamine enabled milder substitution conditions with nucleophiles such as 4-
hydroxybutanone to provide the alkyl carbinolamine 17 or ammonia to give aminal 18 
(Scheme 4). The presence of the amine was confirmed by HRMS and by changes in the 
13C chemical shift of C5; namely, a shift from 95.7 to 82.0 ppm supports formation of an 
aminal at C5. This derivative exhibited excellent stability in water. No trace of AglA by 




To access the unknown methyl-substituted N9 derivative 19, we took advantage 
of the differential acidity of protons in AglA (C5–OH > N9–H > N3–H). Addition of 1.0 
equiv of LiHMDS, presumably led to initial deprotonation of the carbinolamine and 
addition of TMSCl gave an intermediate silylether derivative that was not isolated but 
directly treated with a second equivalent of LiHMDS followed by quenching with 
methyliodide. The silylether was then cleaved by direct addition of TBAF to provide the 
monomethylated compound 19 in good yield (72%). The regiose-lectivity of this 
methylation was confirmed through HMBC correlations. 
 
Structure–activity relationship studies: anticancer activity of AglA derivatives 
AglA derivatives 2–25 were screened against several cancer cell lines and 
primary chronic lymphocytic leukemia (CLL) cells. HeLa cells were studied for 
comparison to published cytotoxicity of previously described AglA derivatives. Among 
the C14 and C15 AglA derivatives, only 14-chloro AglA (3) and the 14-methyl derivative 
(12) retained activity toward CLL albeit with only µM activity (IC50 = 2.82 µM and 7.12 
µM, respectively vs 0.71 µM for AglA, Table 1). Likewise, toward HeLa cells, the choro 
derivative had greater activity than the methyl derivative (IC50 = 0.479 µM and 4.53 µM, 
respectively). Furthermore, the 14-methyl compound (12) showed comparable potency 
when compared to AgelB (4) (HeLa, IC50 = 4.53 µM and 7.85 µM, respectively). Given 
that a bromine atom and a methyl group have similar steric size (VDW radii = 1.85 and 
1.80 Å, respectively) (Wermuth et al., 2015) but different electronic properties, this result 
suggests that the size of the group at C14 is more important than electronic effects when 
considering activity toward HeLa cells. This was further substantiated by comparison to 
the C14-chloro derivative 3 for which the size decreases from 1.85 Å (Br) to 1.75 Å (Cl) 
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and the potency significantly increased (17X toward HeLa cells). However, introduction 
of electron-withdrawing groups at C14 such as acetyl derivative (13) resulted in loss of 
activity (>10 µM and >20 µM for CLL and HeLa, respectively, Table 1). While previous 
reports demonstrated that a phenyl group is tolerated at C13, for example toward triple-
negative breast cancer cells (Li et al., 2013), the introduction of a phenyl (11) or 
ethynylphenyl (14) at C14 led to loss of activity (>10 µM and >20 µM for CLL and HeLa, 
respectively, Table 1). Similarly, the 13,14-diphenyl derivative 10 did not show significant 
activity against HeLa and CLL cell lines. The 15-bromo and 15-methyl derivatives, 5 and 
7, were inactive against HeLa cells (Table 1). Additionally, no activity was observed with 
the bis-methyl compound 8. These results suggest that substitution at C15 is not 






Table 1. Cytotoxicity of AglA derivatives 1–14 and 25 with pyrrole ring 









AglA derivatives 1, 3, 4 and 25 that displayed activity toward CLL were also assayed 
against various cancer cell lines (Table 2, CLL data included for comparison). The 14-
chloro derivative 3 exhibited comparable activity to AglA while AgelB 4 was ~10x less 
potent than AglA toward all cell lines. Notably, compound 25 showed comparable activity 
to that of the parent natural product against Igrov and Ovcar3 (IC50 0.306 and 0.276 µM, 
respectively) whereas against SJSA1, A3 and A431 the IC50 values were above 1 µM.  
 
Consistent with previously reported SAR studies (Guerriero et al., 1994; Stout et 
al., 2014), O-alkylated compounds 15, 17 and 20 suffered from loss of activity toward 
HeLa and CLL cells (IC50 >10–20 µM, Table 3) with the exception of derivative 17. 
However, we determined that AglA was slowly regenerated from alkoxy carbinolamine 
17 in water (t1/2 = 16 h at 25 °C) likely from β-elimination. This suggests that this and 
related alkoxycarbinolamine derivatives of AglA could be useful as prodrugs or 
alternatively the carbinolamine center could serve as a point of attachment for antibody 
drug conjugate synthesis if an appropriate pH sensitive alkoxycarbinolamine is identified 
(Bouchard et al., 2014; Chari et al., 2014). On the other hand, the activity of aminal 18  
Table 2. Antitumor activities of AglA derivatives toward various cancer cell lines 
with pyrrole ring modifications 
17 
 
was significantly reduced toward HeLa cells (0.084 µM to 17 µM, ~200x) and 
primary CLL cells (>30 µM) suggestive of the stability of this aminal derivative (t1/2 = 7 
days at pH = 5 at 37 °C). Introduction of a N9-methyl group in derivative 19 resulted in 








Table 4. Plasma protein properties of AglA (1) and 14-Cl-AglA (3) 
 
 
Protein binding studies 
The propensity of AglA (1) and 14-Cl-AglA (3) to bind to plasma proteins and 
their stability in these media was investigated with both human plasma and fetal bovine 
serum (FBS, Table 4). The cytotoxicity of the compounds did not change dramatically 
when maintained in either human plasma or FBS suggesting that they were not highly 
protein bound. Further studies were performed to verify these results, and indeed full 
recovery of these derivatives was possible also pointing to their high stability. Low 
recovery is often an indication of material loss during the analysis due to compound 








Differential cytotoxicity studies 
The toxicity of AglA (1) and 14-Cl-AglA (3) was compared between CLL cells and 
normal B and T-lymphocytes (Fig. 2). The study revealed that compared to CLL cells, 
AglA was less toxic toward B and T cells from healthy donors. The selectivity for CLL 
leukemia cells was even more apparent for 14-chloro derivative 3. Although both 
compounds did demonstrate toxicities toward normal B lymphocytes, this is generally not 
a concern for future clinical application, as the B cell targeting antibodies rituximab and 
ofatumumab were proven safe for therapeutic treatment of B cell malignancies (Korycka-





Fig. 2. Effect of AglA (1) and 14-Cl-AglA (3) on B and T-cells and all plasma cells 





Synthesis of AglA affinity probes 
Building on the SAR gathered for the C14-methyl and chloro derivatives 3 and 
12, we targeted a photoaffinity probe that could be useful for affinity chromatography 
experiments (Leslie and Hergenrother, 2008; Ziegler et al., 2013). Given the low potency 
exhibited by such derivatives (~0.5-4.5 µM) however, we elected to synthesize a 
photoaffinity probe to improve the possibility of capturing interacting proteins. Toward 
this goal, a trifunctional probe 24 containing both a diazirine for covalent capture of 
putative cellular target(s) through photocrosslinking and an alkyne for subsequent biotin 
attachment to facilitate purification of covalently modified proteins was synthesized 
(Scheme 5). Beginning with previously prepared iodide 2, Stille coupling with a stannyl 
bis-alkyne gave amine 21. Acylation of this amine with diaziridine 22 gave amide 23 in 
modest yield with recovered amine 21. Oxidation of the diaziridine with I2 in methanol 
delivered the trifunctional diazirine probe 24. We were pleased to find that both 
diaziridine 23 and diazirine 24 retained activity toward HeLa cells albeit greatly reduced 







Photoaffinity labeling allows capture of drug-binding proteins and target 
identification by mass spectrometry. To ensure covalent crosslinking occurs, a UV light 
sensitive diazirine derivative is typically incorporated into a probe (Figure 3a, purple), as 
well as a free alkyne moiety (Figure 3a, blue) that is necessary for click chemistry. For 
this approach to be successful, a probe must be designed that can bind to the same 
target proteins and induce the same effects as the parent drug with a similar potency 
(Figure 3b). Unfortunately, our probe lost significant activity compared to parent AglA, 
but we still took a gamble to see if any specific proteins were pulled down and competed 
away in the presence of excess AglA.  
Scheme 5. Synthesis of an AglA trifunctional probe 24. 
22 
 
Labeling was carried out similar to the methods previously used by our group (Head et 
al., 2015), but with rabbit reticulocyte lysate and purified ribosomes. These lysates were 
used because we narrowed down protein translation as the primary target of AglA using 
phenotypic based approaches, which will be further discussed in Chapter 3.  After 
lysates were treated with the probe, they were placed under a UV lamp for 3 min to 
activate the photolabile diazirine and covalently crosslink the probe to its potential 
binding protein(s), after which the samples were denatured by boiling in water. The 
denatured lysates then were reacted with fluor-azide in the presence of copper, which 
reacts with the terminal acetylene of the probe to attach the fluorophore covalently via 
click chemistry. The proteins then were resolved on an SDS/PAGE gel, which was 
scanned on a fluorescence gel scanner to detect fluorescently labeled proteins. In 
comparison to the background bands present in the DMSO control sample, no difference 







Fig. 3. Photoaffinity labeling. (a) AglA probe 24. Essential photoaffinity portions 
highlighted (b) General schematic summarizing the method. Photoaffinity labeling 
was conducted using a fluorescent detection tag, and the gel was scanned for 
fluorescence to detect photolabeled proteins in (c) rabbit reticulocyte lysate and 





In summary, we expanded the SAR profile of the anticancer agent, AglA through 
further investigations of the C14 position of the pyrrole and positions not previously 
investigated, C15 and N9. The 14-Cl-AglA (3) retained activity against various cancer 
cell lines including HeLa, CLL and A431. This AglA derivative also showed better 
selectivity toward CLL cells over B and T-cells than AglA and exhibits low serum protein 
binding and good stability given that recovery from serum was excellent.  
A trifunctional photoaffinity probe of AglA, albeit with low cytotoxic activity relative 
to AglA, was synthesized. Studies toward cellular target identification, using this probe 
were conducted. Many proteins were pulled down, which is likely due to nonspecific 
crosslinking. Unfortunately, no proteins were successfully pulled down and competed 
away, which is important requirement for drug target candidates. These studies, in 
conjunction with previous work by others, demonstrate that few modifications of the AglA 
structure are tolerated while retaining high potency relative to the parent natural product. 
Finally, we demonstrated that alkoxyaminal derivatives of AglA may prove useful as 













Materials and Methods 
General Procedures 
All reactions were performed under a nitrogen atmosphere in ovendried 
glassware. N,N-Dimethylformamide was dried over activated molecular sieves (4 Å). 
Dichloromethane, tetrahydrofuran and methanol were dried by passing through activated 
molecular sieves or alumina. Triethylamine and diisopropylethylamine were distilled from 
calcium hydride. N-Bromosuccinimide and N-iodosuccinimide have been recrystallized 
following reported procedures (Wermuth et al., 2015). Others solvents and reagents 
were used as received from commercially available sources. Reactions were monitored 
by LCMS and TLC. Retention times (TR) are reported in minutes. Low-resolution LCMS 
analyses were conducted in APCI mode with a C18 column (50 x 4.6 mm, 2.7 µm), using 
a gradient mobile phase (5 → 100% MeCN /H2O) in 20 min at 0.2 mL/min. All 
compounds used in biological assays were analyzed by LC-MS and purified to purities of 
≥ 95%. Thin layer chromatography was performed using glass-backed 60Å silica gel F-
254 (250 µm thickness). Developed plates were visualized by UV light and by immersion 
in ceric ammonium molybdate (CAM) stain followed by heating. 1 H and 13C NMR 
spectra were recorded on a 500 MHz (125 MHz) NMR equipped with quad probe for 1 
H{31P}{19F} or a 500 MHz (125 MHz) sNMR equipped with a cryoprobe in CD3OD or 
CDCl3 and referenced to δ 3.31 and 49.0 ppm, and δ 7.27 and 77.16 ppm respectively 
for 1 H and 13C NMR. 19F NMR spectra were recorded on a 500 Varian 470 MHz 
spectrometer. Coupling constants (J) are reported in Hertz (Hz) and multiplicity follows 
normal convention: s, singlet; d, doublet; t, triplet; q, quartet; quint, quintuplet; dd, 
doublet of doublets; dt, doublet of triplets; dt, triplet of doublets; m, multiplet; br s, broad 
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singlet; br dd, broad doublet of doublets; br dt, broad doublet of triplets; (prefix app 
indicates ‘apparent’). High-resolution mass spectra were obtained through the Center for 
Chemical Characterization and Analysis (Texas A&M University). Infrared spectra were 
obtained on a FTIR spectrometer as a thin film on NaCl plates. 
(–)-Agelastatin A 
 
(–)-Agelastatin A (1) was synthesized following the procedure described by 
Movassaghi and co-workers (Movassaghi et al., 2010) in 9 steps from (–)-D-aspartic 
acid: Rf 0.38 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 6.91 (d, J 
= 4.1 Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H), 4.60 (app dt, J = 12.0, 6.0 Hz, 1H), 4.09 (d, J = 
5.4 Hz, 1H), 3.88 (s, 1H), 2.81 (s, 3H), 2.65 (dd, J = 12.9, 6.4 Hz, 1H), 2.10 (app t, J = 
12.6 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 161.4, 161.1, 124.1, 116.1, 113.8, 107.3, 
95.7, 67.4, 62.2, 54.4, 40.0, 24.2; HRMS (+ESI): m/z calcd for C12H13BrNaN4O3 [M+Na]+ 
363.0068, found 363.0075; Chiral HPLC: (–)-agelastatin A was found to be 95% ee 
using the following conditions: Chiralpak AD-H, 0.50 mL/min, 30% i-PrOH/hexanes, TR 
(major) = 11.64 min, TR (minor) = 8.50 min; [α]D 21.4 -90.0 (c = 0.10, MeOH), lit.2 [α]D 
22 -87.6 (c = 0.10, MeOH).  
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*Note: All described AglA derivatives are expected to have the same absolute 
configuration and optical purity as the synthetically derived AglA since no 
transformations described are expected to lead to inversion of all stereocenters. 
 
14-Iodo Agelastatin A (2) 
To a solution of (–)-agelastatin A (1) (10.0 mg, 0.029 mmol, 1 equiv) in 2:1 
THF:H2O (1.5 mL) at 0 °C was added 2,6-di-t-butyl-4-methylpyridine (12.1 mg, 0.059 
mmol, 2 equiv) followed by N-iodosuccinimide (13.2 mg, 0.059 mmol, 2 equiv) and 
In(OTf)3 (1.6 mg, 0.0029 mmol, 0.1 equiv). After stirring at the same temperature for 3 h, 
the reaction mixture was quenched by addition of a small crystal of sodium thiosulfate 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(SiO2, 10% MeOH / CH2Cl2) providing 10 mg (74%) of 14-iodo agelastatin A (2) as a 
colorless solid; Rf 0.40 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 
7.03 (s, 1H), 4.62 (app dt, J = 11.9, 6.0 Hz, 1H), 4.09 (d, J = 5.6 Hz, 1H), 3.87 (s, 1H), 
2.81 (s, 3H,), 2.67 (dd, J = 12.9, 6.4 Hz, 1H), 2.11 (app t, J = 12.7 Hz, 1H); 13C NMR 
(125 MHz, CD3OD) δ 161.4, 160.0, 126.1, 122.3, 113.7, 95.5, 69.0, 67.3, 62.1, 55.9, 




14-chloro-agelastatin A (3) 
 
A solution of (–)-agelastatin A (1) (5.5 mg, 0.012 mmol, 1 equiv) in DMF (0.5 mL) 
was degassed by passage of a stream of argon through the solution for 15 min through 
a stainless steel needle. Palau’chlor
® (3.8 mg, 0.018 mmol, 1.5 equiv) was added and 
the reaction mixture was stirred at 23 °C for 16 h. The reaction mixture was concentrated 
in vacuo and the residue purified by flash column chromatography (SiO2, 10% MeOH / 
CH2Cl2) and then by semi-preparative reverse-phase HPLC (100 x 21.20 mm, 5 µm; 
linear gradient, 5 → 95% CH3CN/H2O with 0.1% of ammonium bicarbonate over 20 min, 
10 mL/min) to yield 14- chloro-agelastatin A (3) (TR = 35.2 min, 1.1 mg, 24%) and 
agelastatin B (4) (TR = 37.6 min, 1.5 mg, 30%) both as colorless solids.  
14-chloro-agelastatin A (3): Rf 0.39 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR 
(500 MHz, CD3OD) δ 6.91 (s, 1H), 4.58 (app dt, J = 11.9, 6.0 Hz, 1H), 4.11 (d, J = 5.3 
Hz, 1H), 3.87 (s, 1H), 2.80 (s, 3H), 2.67 (dd, J = 12.9, 6.4 Hz, 1H,), 2.12 (t, J = 12.6 Hz, 
1H); 13C NMR (125 MHz, CD3OD) δ 161.2, 160.1, 123.7, 116.2, 114.2, 106.2, 95.6, 
67.4, 62.0, 55.0, 39.9, 24.2; HRMS (+ESI): m/z calcd for C12H12BrClNaN4O3 [M+Na]+ 
396.9678, found 396.9687.  
agelastatin B (4): Rf 0.39 (CH2Cl2/ MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, 
CD3OD) δ 6.95 (s, 1H), 4.59 (app dt, J = 11.9, 6.0 Hz, 1H), 4.10 (d, J = 5.4 Hz, 1H), 3.86 
(s, 1H), 2.80 (s, 3H), 2.66 (dd, J = 13.2, 6.6 Hz, 1H), 2.11 (t, J = 12.6 Hz, 1H); HRMS 
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(+ESI): m/z calcd for C12H12Br2NaN4O3 [M+Na]+ 440.9174, found 440.9187. Data 
matched that previously reported (Movassaghi et al., 2010).  
15-bromoagelastatin B (5) 
 
To a solution of (–)-agelastatin A (1) (1.1 mg, 0.0032 mmol, 1 equiv) in DMF (0.2 
mL) was added potassium bromide (1.5 mg, 0.0128 mmol, 4 equiv) and Selectfluor® (4.5 
mg, 0.0128 mmol, 4 equiv). On addition of Selectfluor® the solution turned from colorless 
to bright yellow. The reaction mixture was stirred at 23 °C for 1 h then concentrated in 
vacuo and the residue was purified by pipette flash column chromatography (SiO2, 10% 
of MeOH in MM) and then by semi-preparative reverse-phase HPLC (100 x 21.20 mm, 
5µm; linear gradient, from 5 → 95% CH3CN/H2O with 0.1% of ammonium bicarbonate 
over 20 min, 10 mL/min) to yield agelastatin B (4) (TR = 10.1 min, 0.53 mg, 40%) and 
15-bromoagelastatin A (5) (TR =11.2 min, 0.73 mg, 46%) both as colorless solids.  
15-bromoagelastatin B (5): Rf 0.39 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR 
(500 MHz, CD3OD) δ 4.64 (app dt, J = 12.0, 5.7 Hz, 1H), 4.09 (d, J = 5.4 Hz, 1H), 3.86 
(s, 1H), 2.80 (s, 3H), 2.68 (dd, J = 13.2, 6.6 Hz, 1H), 2.16 (app t, J = 12.6 Hz, 1H); 13C 
NMR (125 MHz, CD3OD) δ 161.3, 159.0, 121.5, 109.0, 105.9, 105.6, 95.5, 67.3, 61.5, 





15-iodo-agelastatin B (6)  
 
To a solution of agelastatin B (4) (1.1 mg, 0.0026 mmol, 1 equiv) in 2:1 THF: H2O 
(0.2 mL) at 0 °C was added 2,6-di-t-butyl-4-methylpyridine (3 mg, 0.013 mmol, 5 equiv) 
followed by I2 (3 mg, 0.026 mmol, 10 equiv) and In(OTf)3 (0.6 mg, 0.001 mmol, 0.4 
equiv). The reaction mixture was stirred at 23 °C for 48 h and after 24 h, additional I2 (3 
mg, 0.026 mmol, 10 equiv) was added. The reaction mixture was quenched by addition 
of a small crystal of sodium thiosulfate and then concentrated in vacuo. The residue was 
purified by semipreparative reverse-phase HPLC (100 x 21.20 mm, 5µm; linear gradient, 
5 → 95% CH3CN/H2O with 0.1% of ammonium bicarbonate over 20 min, 8 mL/min) to 
yield 15- iodoagelastatin B (6) (TR = 15 min, 1 mg, 71%) as thin film: Rf 0.40 (CH2Cl2 / 
MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 4.65 (app dt, J = 11.9, 6.3 Hz, 
1H), 4.08 (br d, J = 5.1 Hz, 1H), 3.86 (s, 1H), 2.80 (s, 3H), 2.68 (br dd, J = 12.8, 6.3 Hz, 
1H), 2.16 (br app t, J = 12.6 Hz, 1H); HRMS (+ESI): m/z calcd for C12H12Br2IN4O3 
[M+H]+ 566.8140, found 566.8186  
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14,15-dimethyl agelastatin A (8) and 15-methyl agelastatin B (7) 
 
A solution of 15-iodo agelastatin B (6) (0.5 mg, 0.9 µmol, 1 equiv) in DMF (0.1 
mL) was degassed by passage of a stream of argon through the solution for 15 min 
through a stainless steel needle. Cs2CO3 (2 mg, 0.006 mmol, 6 equiv) and methylboronic 
acid (0.2 mg, 0.0027 mmol, 3 equiv) were added followed by Pd(PPh3)4 (0.6 mg, 0.6 
µmol, 0.6 equiv). The reaction mixture was heated at 60 °C for 3 h. The reaction mixture 
was filtered, concentrated in vacuo, and purified by semi-preparative reverse-phase 
HPLC (100 x 21.20 mm, 5µm; linear gradient, 5 → 95% CH3CN/H2O with 0.1% of 
ammonium bicarbonate over 20 min, 8 mL/min) to yield 14,15-dimethyl agelastatin A (8) 
(TR = 11.7 min, 0.2 mg, 60%) and 15-methyl-agelastatin B (7) (TR = 12.4 min, 0.1 mg, 
26%) as thin films.  
14,15-bismethyl-agelastatin A (8): Rf 0.41 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H 
NMR (500 MHz, CD3OD) δ 4.53 (app dt, J = 12.0, 6.0 Hz, 1H), 3.99 (d, J = 5.4 Hz, 1H), 
3.83 (s, 1H), 2.80 (s, 3H), 2.59 (dd, J = 13.3, 6.4 Hz, 1H), 2.29 (s, 3H), 2.25 (s, 3H), 2.09 
(app t, J = 12.6 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 160.9, 160.4, 129.9, 126.6, 
116.4, 100.9, 94.6, 67.1, 61.6, 53.1, 39.7, 23.8, 11.3, 9.9, assignments and correlations 
were verified by HSQC and HMBC experiments; HRMS (+ESI): m/z calcd for 
C14H17BrNaN4O3 [M+Na]+ 391.0381 found 391.0389  
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15-methyl-agelastatin B (7): Rf 0.41 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR 
(500 MHz, CD3OD) δ 4.57 (app dt, J = 12.0, 6.0 Hz, 1H), 4.03 (d, J = 5.3 Hz, 1H), 3.85 
(s, 1H), 2.80 (s, 3H), 2.63 (dd, J = 13.1, 6.4 Hz, 1H), 2.35 (s, 3H), 2.09 (app t, J = 12.6 
Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 160.7, 160.2, 127.7, 119.4, 106.9, 103.7, 94.8, 
66.9, 61.3, 54.9, 39.4, 23.6, 11.7, assignments and correlations were verified by HSQC 
and HMBC experiments; HRMS (+ESI): m/z calcd for C13H14Br2NaN4O3 [M+Na]+ 
456.9305 found 456.9291 
 
15-methyl-13-debromo-agelastatin A (9) 
 
To a solution of 15-methyl-agelastatin B (7) (0.5 mg, 0.0011 mmol, 1 equiv) in 
methanol (0.1 mL) was added Et3N (1 µL, 0.0055 mmol, 5 equiv) and Pd/C (10% wt). 
Three cycles of evacuation (aspirator vacuum) and purging with H2 was followed by 
stirring at 23 °C for 1 h under 1 atm H2 (balloon) before being filtered and concentrated 
in vacuo. The mixture was purified by semi-preparative reverse-phase HPLC (100 x 
21.20 mm, 5µm; linear gradient, 5 → 95% CH3CN/H2O with 0.1% of ammonium 
bicarbonate over 20 min, 8 mL/min) to yield 15-methyl-13-debromo agelastatin A (9) (TR 
= 9.1 min, 0.3 mg, quantitative) as a thin film: Rf 0.39 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 
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H NMR (500 MHz, CD3OD) δ 6.88 (d, J = 2.5 Hz, 1H), 6.04 (d, J = 2.2 Hz, 1H), 4.57 (br 
app dt, J = 11.3, 6.0 Hz, 1H), 3.94 (br d, J = 5.2 Hz, 1H), 3.78 (d, J = 1.0 Hz, 1H), 2.79 
(s, 3H), 2.57 (dd, J = 13.3, 6.4 Hz, 1H), 2.35 (s, 3H), 2.26 (dd, J = 13.3, 10.5 Hz, 1H); 
13C NMR (125 MHz, CD3OD) δ 162.8, 161.3, 129.6, 124.3, 118.4, 112.9, 95.7, 67.7, 
62.6, 55.5, 41.3, 24.1, 12.6; assignments and correlations were verified by HSQC and 
HMBC experiments. HRMS (-ESI): m/z calcd for C13H15N4O3 [M-H]- 275.1144 found 
275.1156 
 
14-phenyl-agelastatin A (11) and 13-debromo-13,14-diphenyl-agelastatin A (10)  
 
A solution of 14-iodo-agelastatin A (2) (8 mg, 0.017 mmol, 1 equiv) in THF/H2O 
(0.2: 0.2 mL) was degassed by passage of a stream of argon through the solution for 15 
min through a stainless steel needle and phenyl boronic acid (3.1 mg, 0.025 mmol, 1.5 
equiv) and cesium carbonate (33 mg, 0.102 mmol, 6 equiv) was added, followed by 
Pd(PPh3)4 (3.5 mg, 0.003 mmol, 0.3 equiv). The reaction mixture was heated at 50 °C 
for 2 h. The reaction mixture was concentrated in vacuo. The residue was purified by 
flash column chromatography (SiO2, 10% of MeOH in CH2Cl2) and then by semi-
preparative reverse-phase HPLC (100 x 21.20 mm, 5µm; linear gradient, 5 → 95% 
CH3CN/H2O with 0.1% of ammonium bicarbonate over 20 min, 10 mL/min) to yield 14-
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phenyl-agelastatin A (11) (TR = 11.5 min, 1.3 mg, 19%) and 13- debromo-13,14-
diphenyl agelastatin A (10) (TR = 12.4 min, 1.6 mg, 23%) as colorless solids: Rf 0.40 
(CH2Cl2 / MeOH 9:1) (CAM, UV) for both products. 
14-phenyl agelastatin A (11): 1 H NMR (500 MHz, CD3OD) δ 7.57-7.59 (m, 2H), 
7.41 (app t, J = 7.7 Hz, 2H), 7.29-7.33 (m, 1H), 7.14 (s, 1H), 4.70 (app dt, J = 12.0, 6.0 
Hz, 1H), 4.16 (d, J = 5.6 Hz, 1H), 3.92 (s, 1H), 2.84 (s, 3H), 2.74 (dd, J = 12.9, 6.3 Hz, 
1H), 2.18 (app t, J = 12.7 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 161.4, 161.0, 134.9, 
129.5, 128.8, 128.1, 127.4, 124.2, 114.9, 105.4, 95.7, 67.4, 67.3, 62.1, 54.7, 45.4, 40.0, 
24.2; HRMS (+ESI): m/z calcd for C18H17BrNaN4O3 [M+Na]+ 439.0381, found 439.0372  
13-debromo-13,14-diphenyl agelastatin A (10): 1 H NMR (500 MHz, CD3OD) δ 
7.48-7.51 (m, 3H), 7.38-7.51 (m, 2H), 7.21 (s, 1H), 7.17 (s, 1H), 7.15-7.19 (m, 3H), 7.11-
7.13 (m, 1H), 4.28 (app dt, J = 12.0, 6.0 Hz, 1H), 4.10 (d, J = 5.4 Hz, 1H), 3.83 (s, 1H), 
2.49 (s, 3H), 2.29 (dd, J = 13.1, 6.3 Hz, 1H), 2.21 (app t, J = 12.7 Hz, 1H); 13C NMR 
(125 MHz, CD3OD) δ 161.9, 161.3, 136.1, 135.1, 132.4, 131.8, 130.3, 130.2, 130.1, 
129.3, 128.7, 127.1, 126.3, 122.6, 114.7, 95.4, 67.2, 62.4, 53.7, 46.4, 40.6, 23.8; HRMS 
(+ESI): m/z calcd for C24H22NaN4O3 [M+Na]+ 464.1589, found 464.1583 







A solution of 14-iodo-agelastatin A (2) (3 mg, 0.0065 mmol, 1 equiv) in 
DMF/Et3N (0.1:0.05 mL) was degassed by passage of a stream of argon through the 
solution for 15 min through a stainless steel needle and tetramethyl tin (4 µL, 0.026 
mmol, 4 equiv) was added, followed by Pd(PPh3)4 (3.0 mg, 0.0026 mmol, 0.4 equiv). The 
reaction mixture was heated at 60 °C for 3 h. The reaction mixture was filtered off, 
concentrated in vacuo, and purified by semipreparative reverse-phase HPLC (100 x 
21.20 mm, 5µm; linear gradient, 5 → 95% CH3CN/H2O with 0.1% of ammonium 
bicarbonate over 20 min, 8 mL/min) to yield 14- methyl agelastatin A (12) (TR = 10.3 
min, 0.6 mg, 26%) as thin film: Rf 0.41 (CH2Cl2/ MeOH 9:1) (CAM, UV); 1 H NMR (500 
MHz, CD3OD) δ 6.80 (s, 1H), 4.55 (app dt, J = 12.0, 6.0 Hz, 1H), 4.06 (d, J = 5.4 Hz, 
1H), 3.86 (s, 1H), 2.80 (s, 3H), 2.62 (dd, J = 13.1, 6.5 Hz, 1H), 2.07 (app t, J = 12.6 Hz, 
1H), 2.04 (s, 3H); 13C NMR (125 MHz, CD3OD) δ 160.7, 160.4, 122.4, 121.2, 116.0, 
106.3, 94.8, 67.3, 61.9, 54.4, 39.6, 23.8, 11.2, assignments and correlations were 
verified by HSQC and HMBC experiments; HRMS (+ESI): m/z calcd for 











14-acetyl agelastatin A (13) 
 
A solution of 14-iodo agelastatin A (2) (2 mg, 0.0043 mmol, 1 equiv) in DMF (0.2 
mL) was degassed by passage of a stream of argon through the solution for 15 min 
through a stainless steel needle and the vinyl stannane derivative (6.0 mg, 0.017 mmol, 
4.0 equiv) was added, followed by Pd(PPh3)4 (3.0 mg, 0.0026 mmol, 0.6 equiv). The 
reaction mixture was heated at 60 °C for 5 h. The reaction mixture was filtered and 
concentrated in vacuo. The residue was dissolved in a 0.2 M solution of sodium acetate 
buffer (pH = 5) and stirred at 23 °C for 16 h. The reaction mixture was concentrated in 
vacuo and purified by semi-preparative reversephase HPLC (100 x 21.20 mm, 5µm; 
linear gradient, 5 → 95% CH3CN/H2O with 0.1% of ammonium bicarbonate over 20 min, 
8 mL/min) to yield 14-acetyl agelastatin A (13) (TR = 8.55 min, 0.74 mg, 46%) as a 
colorless solid: Rf 0.43 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 
7.44 (s, 1H), 4.72 (app dt, J = 12.1, 6.1 Hz, 1H), 4.12 (d, J = 5.4 Hz, 1H), 3.90 (s, 1H), 
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2.82 (s, 3H), 2.73 (dd, J = 13.1, 6.4 Hz, 1H), 2.49 (s, 3H), 2.15 (app t, J = 12.7 Hz, 1H); 
13C NMR (125 MHz, CD3OD) δ 193.2, 160.2, 124.2, 123.9, 116.6, 110.0, 94.3, 67.0, 
61.6, 54.3, 39.2, 28.3, 23.9 (due to small quantities obtained, C=O amide not observed), 
assignments and correlations were verified by HSQC and HMBC experiments; HRMS 
(+ESI): m/z calcd for C14H15BrNaN4O4 [M+Na]+ 405.0174, found 405.0177 
14-ethynylphenyl agelastatin A (14)  
 
A solution of 14-iodo agelastatin A (2) (5 mg, 0.010 mmol, 1 equiv) in DMF (0.5 
mL) was degassed by passage of a stream of argon through the solution for 15 min 
through a stainless steel needle and stannane derivative (10.0 µL, 0.030 mmol, 3 equiv) 
was added, followed by Pd(PPh3)4 (3.5 mg, 0.003 mmol, 0.3 equiv). The reaction mixture 
was heated at 60 °C for 3 h. The reaction mixture was concentrated in vacuo. The 
residue was purified by flash column chromatography (SiO2, 10% of MeOH in CH2Cl2) 
and by semi-preparative reverse-phase HPLC (100 x 21.20 mm, 5µm; linear gradient, 5 
→ 95% CH3CN/H2O with 0.1% of ammonium bicarbonate over 20 min, 10 mL/min) to 
yield 14-ethynylphenyl agelastatin A  (TR = 12.7 min, 2.4 mg, 55%) and recovered 14-
iodo agelastatin A (2) (TR = 10.3 min, 1.5 mg) both as colorless solids: Rf 0.39 (CH2Cl2 / 
MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 7.48 (m, 2H), 7.35 (m, 3H), 7.05 
(s, 1H), 4.63 (app dt, J = 11.9, 6.1 Hz, 1H), 4.13 (d, J = 5.4 Hz, 1H), 3.89 (s, 1H), 2.82 (s, 
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3H), 2.71 (dd, J = 12.9, 6.3 Hz, 1H), 2.15 (app t, J = 12.6 Hz, 1H); 13C NMR (125 MHz, 
CD3OD) δ 161.4, 160.4, 132.3 (2), 129.6, 129.4, 125.4, 124.1, 117.5, 111.9, 110.0, 95.6, 
92.8, 82.4, 67.4, 67.3, 62.0, 55.0, 39.9, 24.2; HRMS (+ESI): m/z calcd for 




To a solution of 4-azidobutrylamine (Goddard-Borger and Stick, 2007) (500 mg, 
3.87 mmol, 1 equiv) was added benzylamine (0.84 mL, 7.75 mmol, 2 equiv), HOBt (1 g, 
7.75 mmol, 2 equiv), DIC (1.22 mL, 7.75 mmol, 2 equiv) and DIPEA (2 mL, 11.61 mmol, 
3 equiv). The solution was stirred at 23 °C for 16 h and quenched with 0.5 M aqueous 
solution of HCl. The combined mixture was extracted with diethyl ether (3 x 15 mL). The 
organic extract was washed with brine (3 x 15 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The resulting colorless solid was purified by flash 
column chromatography (SiO2, 20 → 50% EtOAc/hexanes) providing 385 mg (46%) of 
4-Azido-N-benzylbutyramide (A) as a colorless solid: m.p. 65-67°C; Rf 0.65 (50% EtOAc 
/hexanes) (CAM, weak UV active); 1 H NMR (500 MHz, CDCl3) δ 7.34 (dt, J = 6.6, 1.5 
Hz, 2H), 7.29 (dd, J = 7.4, 1.4 Hz, 1H), 7.26 (br d, J = 7.8 Hz, 2H), 4.38 (d, J = 5.8 Hz, 
2H), 3.29 (br dt, J = 6.6, 1.5 Hz, 2H), 2.29 (br dt, J = 7.4, 1.3 Hz, 2H,), 1.89 (m, 2H); 13C 
NMR (125 MHz, CDCl3) δ 172.0, 138.3, 128.4 (2), 127.3 (2), 127.1, 50.6, 43.2, 32.8, 
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24.7; IR (cm-1 ) 3230, 2105 (N3), 1682 (C=O); HRMS (+ESI): m/z calcd for C11H16N4O 
[M+H]+219.1247 found 219.1294 
 
O-Triazole derivative of agelastatin A (15) 
 
To a solution of O-4’-pentynyl agelastatin A (20) (3.0 mg, 7.40 µmol, 1 equiv) and 
4-azido-Nbenzylbutyramide (A) (3.22 mg, 14.8 µmol, 2 equiv) in THF (0.2 mL) was 
added a freshly prepared CuSO4 / sodium ascorbate solution (the solution was made 
from mixing CuSO4- 5H2O, 2.2 µmol, 0.3 equiv and sodium ascorbate, 22.2 µmol, 3 
equiv in H2O (0.2 mL) until the initial black color turned yellow). The mixture was stirred 
at 50 °C for 5 h and concentrated in vacuo. The residue was purified by semi-preparative 
reverse-phase HPLC (100 x 21.20 mm, 5µm; linear gradient, 5 → 70% CH3CN/H2O with 
0.1% of ammonium bicarbonate over 20 min, 10 mL/min) to yield the O-triazole 
derivative of agelastatin A 15 (TR = 14.7 min, 3.5 mg, 76%) as a colorless solid: Rf 0.60 
(CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 7.73 (s, 1H), 7.29 
(overlapping br app q, J = 7.4 Hz, 2H), 7.27 (overlapping br app d, J = 8.1 Hz, 2H), 7.23 




(app dt, J = 12.0, 6.1 Hz, 1H), 4.41 (t, J = 6.6 Hz, 2H), 4.35 (s, 2H), 4.09 (d, J = 5.4 Hz, 
1H), 4.08 (s, 1H), 3.37 (br dt, J = 9.0, 6.3 Hz, 1H), 3.27 (br dt, J = 9.0, 6.1 Hz, 1H), 2.79 
(dt, J = 7.5, 2.6 Hz, 2H), 2.75 (s, 3H), 2.66 (dd, J = 13.3, 6.3 Hz, 1H), 2.26-2.18 (m, 4H), 
2.16 (app t, J = 12.7 Hz, 1H), 1.96 (br app quint, J = 6.5 Hz, 1H); 13C NMR (125 MHz, 
CD3OD) δ 174.3, 161.6, 161.0, 148.5, 140.0, 129.6 (2), 128.6 (2), 128.2, 124.1, 123.5, 
116.1, 113.9, 107.3, 99.8, 62.9, 62.1, 61.5, 53.7, 50.6, 44.2, 39.3, 33.4, 30.2, 27.3, 24.8, 
22.9; HRMS (+ESI): m/z calcd for C28H34BrN8O4 [M+H]+ 625.1887, found 625.1876 
 






A solution of (–)-agelastatin A (1) (1 mg, 0.0029 mmol, 1 equiv) in pyridine (0.1 
mL) was cooled at 0 °C and acetic anhydride was added dropwise (0.3 mL). The 
reaction mixture was slowly allowed to warm up to 23 °C and stirred for 16 h. The 
reaction mixture was concentrated in vacuo. The residue was dissolved in 4-
hydroxybutanone (0.1 mL) and stirred at 23 °C for 48 h. The reaction mixture was 
purified by semi-preparative reverse-phase HPLC (100 x 21.20 mm, 5µm; linear 
gradient, 5 → 95% CH3CN/H2O with 0.1% of ammonium bicarbonate over 20 min, 8 
mL/min) to yield O-(butan-3’-one)-agelastatin A  (TR = 11.1 min, 0.70 mg, 59%) as a 
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colorless solid: Rf 0.81 (CH2Cl2/ MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 
6.91 (d, J = 4.1 Hz, 1H), 6.32 (d, J = 4.1 Hz, 1H), 4.60 (app dt, J = 12.1, 6.1 Hz, 1H), 
4.15 (s, 1H), 4.11 (d, J = 5.6 Hz, 1H), 3.60 (br dt, J = 9.2, 5.9 Hz, 1H), 3.51 (br dt, J = 
9.2, 5.9 Hz, 1H), 2.81 (s, 3H), 2.77 (app t, J = 5.9 Hz, 2H), 2.65 (dd, J = 13.2, 6.4 Hz, 
1H), 2.17 (s, 3H,), 2.12 (app t, J = 12.7 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 209.7, 
161.1, 160.1, 124.1, 116.1, 113.9, 107.3, 99.7, 62.1, 61.5, 58.9, 53.6, 43.1, 39.1, 30.4, 
24.7; HRMS (+ESI): m/z calcd for C16H20BrN4O4 [M+H]+ 411.0668, found 411.0653 
 
5-amino agelastatin A derivative 18  
 
A solution of (–)-agelastatin A (1) (0.8 mg, 0.0023 mmol, 1 equiv) in pyridine (0.1 
mL) was cooled to 0 °C and acetic anhydride was added dropwise (0.3 mL). The 
reaction mixture was allowed to slowly warm to 23 °C and stirred for 16 h. The reaction 
mixture was concentrated in vacuo and the residue was dissolved in liquid ammonia (3-5 
mL) at -78 °C and stirred at reflux (-30 °C) for 3 h. The reaction mixture was allowed to 
warm up to 23 °C (to allow ammonia to evaporate) and purified by semi-preparative 
reverse-phase HPLC (100 x 21.20 mm, 5µm; linear gradient, 5 → 95% CH3CN/H2O with 
0.1% of ammonium bicarbonate over 20 min, 8 mL/min) to yield 5-amino agelastatin A 
derivative 18 (TR = 9.0 min, 0.42 mg, 54%) and agelastatin A (1) (TR = 10.1 min, 0.35 
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mg) as thin films: Rf 0.25 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) 
δ 6.90 (d, J = 4.2 Hz, 1H), 6.32 (d, J = 4.2 Hz, 1H), 4.66 (app dt, J = 12.0, 6.0 Hz, 1H), 
4.09 (d, J = 5.5 Hz, 1H), 3.85 (s, 1H), 2.80 (s, 3H), 2.60 (dd, J = 13.2, 6.6 Hz, 1H), 1.98 
(app t, J = 12.6 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 161.4, 161.1, 124.2, 116.0, 
113.8, 107.2, 82.0, 67.9, 63.0, 54.9, 40.8, 24.1; HRMS (+ESI): m/z calcd for 
C12H16BrN5O3 [M+H]+ 340.0410, found 340.0401 
(±)-9-methyl-agelastatin A (19)  
 
To a solution of (±)-agelastatin A (2.0 mg, 5.9 µmol, 1 equiv) in DMF (0.5 mL) 
was added a 1.0 M solution of LiHMDS in THF (6.4 µL, 6.4 µmol, 1.1 equiv) at 23 oC. 
After 30 min, a 1.0 M solution of TMSCl in THF (5.9 µL, 5.9 µmol, 1.0 equiv) was added. 
Following another 30 min of stirring, a 1.0 M solution of LiHMDS in THF (6.4 µL, 6.4 
µmol, 1.1 equiv) was added. After an additional 30 minutes of stirring, a 0.5 M solution of 
MeI in THF (11.7 µL, 5.9 µmol, 1.0 equiv). Following 30 minutes of stirring, TBAF (41 µL, 
41.0 µmol, 7.0 equiv) was added and after stirring for 30 min, a 0.5 mL of saturated 
NH4Cl solution was added. The reaction mixture was then filtered through a short silica 
gel plug eluting with 20% MeOH/CH2Cl2. The filtrate was concentrated in vacuo to give a 
colorless residue. The residue was purified by preparative TLC eluting and washing with 
10% MeOH in CH2Cl2 to give 1.5 mg (72%) of (±)-9-methyl agelastatin A (19) as a 
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colorless solid: Rf 0.26 (CH2Cl2/ MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 
6.89 (d, J = 4.0 Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H), 4.70 (dt, J = 12.0, 6.0 Hz, 1H), 4.16 (s, 
1H), 4.02 (d, J = 6.0 Hz, 1H), 3.14 (s, 3H), 2.81 (s, 3H), 2.66 (dd, J = 13.0, 6.5 Hz, 1H), 
2.10 (dd, J = 13.0, 12.0 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 161.7, 159.9, 124.3, 
116.1, 114.1, 106.4, 94.8, 68.6, 66.0, 54.2, 41.0, 31.0, 24.2 HRMS (-ESI): m/z calcd for 
C13H14BrN4O3 [M-H]- 353.0249 found 353.0233 
 
O-4’-pentynyl agelastatin A (20)  
 
A solution of (–)-agelastatin A (1) (5.0 mg, 0.014 mmol, 1 equiv) in 4-pentyn-1-ol 
(0.3 mL) was stirred with 20 mg of Dowex 50W-8X (200-400 mesh, H+ form, prewashed 
with 1M HCl, rinsed with distilled H2O and dried under vacuum for 2 days) at 50 °C for 2 
h then 16 h at 23 °C. The mixture was filtered and the filtrate concentrated in vacuo. The 
residue was purified by semi-preparative reverse-phase HPLC (100 x 21.20 mm, 5µm; 
linear gradient, 5 → 95% CH3CN/H2O with 0.1% of ammonium bicarbonate over 20 min, 
10 mL/min) to yield O-4’- pentynyl agelastatin A (20) (TR = 14.3 min, 3.4 mg, 60%) as a 
colorless solid: Rf 0.75 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 
6.92 (d, J = 4.1 Hz, 1H), 6.34 (d, J = 4.1 Hz, 1H), 4.62 (app dt, J = 12.0, 6.1 Hz, 1H), 
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4.12 (d, J = 5.6 Hz, 1H), 4.09 (s, 1H), 3.46 (dt, J = 9.0, 6.1 Hz, 1H), 3.38 (br dt, J = 8.9, 
6.2 Hz, 1H), 2.81 (s, 3H), 2.68 (dd, J = 13.2, 6.5 Hz, 1H), 2.29 (m, 2H), 2.26 (br app t, J 
= 2.6 Hz, 1H), 2.18 (app t, J = 12.7 Hz, 1H), 1.77-1.80 (m, 2H); 13C NMR (125 MHz, 
CD3OD) δ 161.7, 161.0, 124.1, 116.1, 113.9, 107.3, 99.7, 84.1, 70.3, 70.2, 62.2, 61.6, 
53.7, 39.2, 29.5, 24.8, 15.8; HRMS (+ESI): m/z calcd for C17H20BrN4O3 [M+H]+ 




To a solution of dipropargyl amine (100 mg, 1.07 mmol, 1 equiv) in THF (7 mL) at 
-78 °C was added dropwise a 1.7 M solution of tert-butyllithium in THF (0.63 mL, 1.07 
mmol, 1 equiv). The reaction mixture was maintained at -78 oC for 1 h before a pre-
cooled solution of c Hx3SnCl (433 mg, 1.07 mmol, 1 equiv) in THF (3 mL) was added. 
The reaction mixture was slowly allowed to warm to 23 °C with stirring. The reaction was 
quenched with saturated aqueous solution of NaHCO3 and extracted with Et2O (3X). The 
combined organic layers were washed with brine, dried over MgSO4 and filtered off. The 
solvent was removed under reduced pressure. The residue was purified by flash column 
chromatography (SiO2, 5% EtOAc/hexanes w/ 1% Et3N → 10% EtOAc/hexanes w/ 2% 
Et3N) providing 152 mg (31%) of dipropargylamine stannane (B) as colorless oil and 204 
mg (23%) of dipropargylamine distannane (C) as a colorless solid:  
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Dipropargylamine stannane (B): Rf 0.31 (9:1 EtOAc/hexanes) (CAM); 1 H NMR 
(300 MHz, CDCl3) δ 3.53-3.56 (m, 4H), 2.21 (t, J = 2.4 Hz, 1H), 1.86-1.90 (m, 6H), 1.60-
1.70 (m, 12H), 1.56-1.58 (m, 6H), 1.22-1.36 (m, 9H); 13C NMR (74.5 MHz, CDCl3) δ 
108.1, 86.7, 81.7, 71.6, 38.5, 36.9, 32.3, 32.2, 32.0, 29.5, 29.1, 28.7, 27.9, 27.1; HRMS 
(+ESI): m/z calcd for C24H40NSn [M+H]+ 462.2183, found 462.2172  
 
Dipropargylamine distannane (C): Rf 0.53 (9:1 EtOAc/hexanes) (CAM) 1 H NMR 
(300 MHz, CDCl3) δ 3.57 (app t, J = 2.4 Hz, 4H), 1.82-1.91 (m, 12H), 1.61-1.70 (m, 
24H), 1.57 (br s, 12H), 1.24-1.34 (m, 18H); HRMS (+ESI): m/z calcd for C42H72NSn2 
[M+H]+ 830.3709, found 830.3715 
 
14-dipropargylamine agelastatin A derivative 21  
 
To a solution of 14-iodo-agelastatin A (7 mg, 0.015 mmol, 1 equiv) in DMF (0.4 
mL) was added stannane derivative (B) (21 mg, 0.045 mmol, 3 equiv). The reaction 
mixture was degassed by passage of a stream of argon through the solution for 15 min 
through a stainless steel needle and then Pd(PPh3)4 (7.0 mg, 0.084 mmol, 0.4 equiv) 
was added and the reaction mixture was heated at 60 °C for 3 h. The reaction mixture 
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was allowed to cool to 23 °C and charcoal (200 mg) was added. After 10 min at 23 oC, 
the reaction mixture was filtered and concentrated in vacuo. The residue was purified by 
flash column chromatography (SiO2, 10% MeOH/CH2Cl2 w/ 1% Et3N) providing 2.5 mg 
(40%) of 14-dipropargylamine agelastatin A derivative 21 as a colorless solid: Rf 0.36 
(CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 6.96 (s, 1H), 4.59 (app 
dt, J = 11.9, 6.0 Hz, 1H), 4.10 (d, J = 5.3 Hz, 1H), 3.87 (s, 1H), 3.70 (s, 2H), 3.54 (br d, J 
= 2.7 Hz, 2H), 2.80 (s, 3H), 2.67 (br dd, J = 13.2, 6.6 Hz, 1H), 2.64 (br t, J = 2.5 Hz, 1H), 
2.10 (app t, J = 12.7 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 161.4, 160.4, 123.9, 
117.7, 111.7, 109.8, 95.6, 89.6, 81.3, 77.2, 73.6, 67.4, 62.0, 54.9, 39.8, 37.8, 37.0, 24.2; 
HRMS (+ESI): m/z calcd for C18H19BrN5O3 [M+H] + 432.0672, found 432.0674. 
 
4-(3-(trifluoromethyl)diaziridin-3-yl)benzoic acid (22)  
 
The diaziridine 22 was prepared according to published procedures (Bender et al., 2007; 




Diaziridine agelastatin A derivative 23  
 
To a solution of 14-dipropargylamine-agelastatin A (21) (3.0 mg, 0.007 mmol, 1.0 
equiv) in DMF (0.4 mL) at 0 °C was added trifluoromethyldiaziridine carboxylic acid 22 
(1.9 mg, 0.008 mmol, 1.2 equiv), HOBt (1.0 mg, 0.007 mmol, 1.0 equiv), Et3N (2 µL, 
0.011 mmol, 1.5 equiv) and DIC (1.3 µL, 0.008 mmol, 1.2 equiv). The mixture was stirred 
at 0 °C and allowed to warm to 23 °C overnight. The reaction mixture was concentrated 
in vacuo and the residue was purified by pipette flash column chromatography (SiO2, 
10% of MeOH in CH2Cl2 with 1% of NH4OH) and then by semi-preparative reverse-
phase HPLC (100 x 21.20 mm, 5µm; linear gradient, 5 → 95% CH3CN/H2O with 0.1% of 
ammonium bicarbonate over 20 min, 10 mL/min) to deliver the diaziridine agelastatin A 
probe 23 (TR = 11.0 min, 1.1 mg, 24%) as a 1:1 mixture of amide rotamers and as a thin 
film.  
Diaziridine agelastatin A derivative (23): Rf 0.35 (CH2Cl2 / MeOH 9:1) (CAM, UV); 
1 H NMR (500 MHz, CD3OD) δ 7.77 (br d, J = 7.1 Hz, 2H), 7.65 (br s, 2H), 7.01 (s, 1H), 
4.68 (m, 1H), 4.61 (app ddd, J = 12.9, 12.2, 6.1 Hz, 1H), 4.49 (m, 1H), 4.39 (m, 1H), 4.23 
(m, 1H), 4.11 (d, J = 5.4 Hz, 1H), 6.88 (s, 1H), 2.81 (s, 3H), 2.68 (br dd, J = 13.0, 6.5 Hz, 
1H), 2.13 (app t, J = 12.6 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 161.3, 160.8, 137.5, 
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130.4, 129.7, 127.8, 124.9, 124.0, 117.2, 112.3, 95.7, 67.5, 66.9, 66.4, 61.5, 54.4, 39.3, 
35.2, 23.6 (due to small quantities and slow relaxation time, 8 carbons were not 
observable; extended reaction times were precluded due to instability concerns), 
assignments and correlations were verified by HSQC and HMBC experiments; 19F NMR 
(470 MHz, CD3OD) δ -76.67; HRMS (+ESI): m/z calcd for C27H24BrF3N7O4 [M+H]+ 
646.1025, found 646.1041. 
 
Diazirine Agelastatin A derivative 24  
 
To a solution of the diaziridine agelastatin A derivative 23 (1 mg, 0.0015 mmol, 1 
equiv) in MeOH (0.1 mL) protected from light at 0 °C was added Et3N (1.3 µL, 0.009 
mmol, 6 equiv) and I2 (0.6 mg, 0.0023 mmol, 1.5 equiv). The mixture was allowed to 
warm to 23 °C for 3 h and concentrated in vacuo. The residue was purified by pipette 
flash column chromatography protected from light (SiO2, 9% MeOH, 1% NH4OH in 
CH2Cl2) to yield diazirine agelastatin A derivative 24 (1.14 mg as a mixture of 1:4 
probe/Et3N; 0.800 mg, 83% estimated by NMR of free probe) as a thin film: Rf 0.40 (9% 
MeOH, 1% NH4OH in CH2Cl2) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 7.68 (br d, J = 
7.6 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.00 (s, 1H,), 4.60 (app dt, J = 11.9, 6.3 Hz, 1H) 
overlap with 4.60 (m, 1H), 4.49 (m, 1H), 4.37 (m, 1H), 4.22 (m, 1H), 4.10 (d, J = 5.4 Hz, 
1H), 3.88 (s, 1H), 2.81 (s, 3H,), 2.69 (br dd, J = 13.3, 6.2 Hz, 1H), 2.13 (app t, J = 12.6 
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Hz, 1H); 19F NMR (470 MHz, CD3OD) δ -66.9; HRMS (+ESI): m/z calcd for 
C27H21BrLiF3N7O4 [M+Li]+ 650.0951, found 650.0933 
 
13-debromo-13-methyl-agelastatin A (25)  
 
A solution of (–)-agelastatin A (1) (5 mg, 0.015 mmol, 1 equiv) in DMF/Et3N 
(0.3/0.1 mL) was degassed by passage of a stream of argon through the solution for 15 
min through a stainless steel needle and tetramethyltin (9.0 µL, 0.06 mmol, 4 equiv) was 
added, followed by Pd(PPh3)4 (7.0 mg, 0.006 mmol, 0.4 equiv). The reaction mixture was 
heated at 60 °C for 16 h. The reaction mixture was concentrated in vacuo. The residue 
was purified by flash column chromatography (SiO2, 10% of MeOH in CH2Cl2) and then 
by semi-preparative reverse-phase HPLC (100 x 21.20 mm, 5µm; linear gradient, 5 → 
95% CH3CN/H2O with 0.1% of ammonium bicarbonate over 20 min, 10 mL/min) to yield 
13-debromo-13-methyl-agelastatin A (25) (TR = 8.0 min, 3.0 mg, 71%) as a colorless 
solid: Rf 0.35 (CH2Cl2 / MeOH 9:1) (CAM, UV); 1 H NMR (500 MHz, CD3OD) δ 6.83 (d, J 
= 3.6 Hz, 1H), 6.01 (d, J = 3.6 Hz, 1H), 4.54 (app dt, J = 12.0, 6.1 Hz, 1H), 4.03 (d, J = 
5.3 Hz, 1H), 3.87 (s, 1H), 2.80 (s, 3H), 2.60 (dd, J = 13.0, 6.4 Hz, 1H), 2.28 (s, 3H), 2.09 
(app t, J = 12.6 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 162.3, 161.5, 134.7, 121.6, 
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115.5, 110.4, 95.9, 67.5, 62.5, 52.8, 40.2, 24.2, 11.4; HRMS (+ESI): m/z calcd for 
C13H17N4O3 [M+H]+ 277.1301, found 277.1290. 
 
Photoaffinity labeling 
Photoaffinity labeling was performed as described (Head et al., 2015), with 
modifications. Lysates were diluted to 200 ul, in ice cold 1x PBS (pH 8.5), followed by 
pretreatment with 100 uM competitor (AglA (1)) or an equal volume of DMSO vehicle for 
30 min, before the addition of 1 uM probe or DMSO. After 1-h incubation with the probe, 
lysates were placed 3 cm below a Spectroline FC100 365 nm UV lamp for 1 min on ice 
to minimize heating from the lamp. After irradiation, samples were incubated at 95 °C for 
5 min to denature all the proteins. For the click reaction with fluor-azide, 40 µL of lysate 
was removed and transferred to a new tube, and 0.2 µL Alexa Fluor 647 azide (1 mM 
stock solution in DMSO), 0.58 µL TCEP (100 mM stock with four equivalents NaOH 
added), and 3.38 µL TBTA (1.7 mM stock in a 4:1 ratio of t-butanol to DMSO) were 
added sequentially and vortexed to mix. Then CuSO4-5H2O (1.14 µL, 50 mM stock in 
water) was added to start the reaction. The samples were vortexed again briefly and 
were incubated at room temperature for 30 min in the dark. Then aliquots of 50 µL 2× 
SDS sample buffer were added, and samples were subjected to SDS/PAGE before 
being scanned on a Typhoon FLA 9500 gel scanner (GE Healthcare Life Sciences) 






Cell proliferation assay 
HeLa cells were seeded at 3000 cells per well in 96-well plates and cultured in 
DMEM plus 10% FBS and 1% Penicillin Streptomycin at 37 °C with 5% CO2. Twenty four 
hours after seeding, drugs were added and incubation was continued for an additional 
24 h. An aliquot of 1 µCi of [3H]-thymidine (Perkin Elmer) was added per well and 
incubation was continued for an additional 6 h. Cells were harvested onto a Printed 
Filtermat A glass fiber filter (Perkin Elmer) using Tomtec Harvester 96 Mach III and filters 
were immersed in Betaplate Scint (Perkin Elmer) scintillation fluid, followed by 
scintillation counting on 1450 Microbeta JET (Perkin Elmer).  
 
Patients 
Samples from 12 CLL patients and three normal donors were used in this study. 
Median age of the patient was 65.5 (52 to 78) with 7 male patients and 5 female 
patients. Their median white blood cell count was 67.7 (14.6 to 214.6). The median 
lymphocyte percentage was 88% (73 to 94%). Majority of the patients was untreated. 
Approval was obtained from the University of Texas M. D. Anderson Cancer Center 
Institutional Review Board for this investigation, and all patients and donors agreed to 







CLL cells isolation and culture 
Peripheral blood from the CLL patients were collected in heparin vacutainer 
tubes and centrifuged at 1500 rpm for 15 min to separate the plasma (upper layer), 
which was removed and saved for cell culture. The lower layer was diluted with 
phosphate-buffered saline (PBS), and the mononuclear cells were isolated by Ficoll 
density gradient centrifugation. The isolated CLL cells were cultured at 1 × 107 cells/mL 
in RPMI 1640 medium containing 10% of autologous plasma or 10% fetal bovine serum 
(FBS).  
Quantitation of cell death 
The CLL cells or normal lymphocytes were incubated with increasing 
concentrations of AglA or analogues for 24h, in RPMI 1640 media supplemented with 
either 10% patient plasma or 10% FBS. Cell viability was measured by Annexin 
V/propidium iodide double staining followed by flow cytometry. After the drug treatment, 
CLL cells (1x106 cells) were incubated in dark for 15 min at room temperature in 200 μL 
binding buffer with 5 mL annexin V-Cy5. After staining, 300 μL binding buffer with 5 μL of 
50 μg/mL PI were added to each tube. Samples were analyzed immediately with a 
Becton Dickinson C6 flow cytometer. Cells stained positive for either annexin V or PI 
were considered dead cells. Normal B and T cells were identified by their positive 
staining for CD19 (B cells) or CD3 (T cells).  
Plasma protein binding analysis 
Plasma protein binding of the compounds was analyzed by equilibrium dialysis 
followed by liquid chromatography-mass spectrometry, in the Pharmaceutical Science 
Facility in the Institute for Applied Cancer Science, M. D. Anderson Cancer Center. All 
measurements were performed in triplicates.  
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SJSA1, A431, A3, Ovcar3 and Igrov cells isolation and culture 
SJSA1, A431 and Ovcar3 cells were from ATCC. Igrov cells were a gift from 
National Cancer Institute on behalf of Dr. J. Benard. A3 was the A431 cells expressing 
the mesothelin protein, generated at Morphotek. Igrov, SJSA1, A431 and Ovcar3 cells 
were cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal 
bovine serum, 2 mM glutamine, 1X MEM. Non-essential amino acids, 50 unit/mL 
penicillin, and 50 mg/mL streptomycin. A3 cells were cultured in the same medium with 
10 mg/mL zeocin. Cells were seeded at 10,000 cells/well in 96 well tissue culture plates, 
incubated at 37°C, 5% CO2 for overnight. All the compounds were dissolved in DMSO at 
6 mM. Then compounds were serial diluted in the medium and added to the cells, 
incubated for additional 48 hours. At the end of the assay, discarded the medium, 
washed the plates with 200 mL DPBS, stained with 0.2% crystal violet solution for 15 
minutes at room temperature, then washed with tap water, air dried, and dissolved with 








































We show that AglA selectively inhibits protein synthesis, using a “top-down” 
target elucidation approach as described previously (Titov and Liu, 2012). By taking 
advantage of the extensive prior knowledge of eukaryotic translation, we systematically 
examined the effects of AglA on multiple steps of protein synthesis and determined that 
AglA inhibits translation elongation by binding within the ribosome, the heart of protein 
translation. Composed of an intricate complex of ribosomal RNA (rRNA) and proteins, 
the ribosome acts in conjunction with protein factors to catalyze templated peptide 
formation (Fig. 4). Each ribosome is composed of two subunits: The small 40S subunit 
(30S in bacteria and archaea) and the large 60S (50S) complex. (Cannone et al., 2002; 
Jenner et al., 2012) 
The structure and sequence of ribosomal RNA have changed only little in the 
course of billions of years; the overall tertiary folds of the ribosomal components have 
been retained over the course of evolution. Because of its strong sequence conservation 
and slow mutation rate, ribosomal RNA presents an excellent evolutionary clock, though 
eukaryotic and prokaryotic ribosomes do differ from one another in a number of ways. 
Compared to its bacterial counterpart, the size of eukaryotic ribosomes is larger. The 
small bacterial subunit entails one molecule of rRNA (16S) and 21 proteins, while 
eukaryotes typically contain some 30 proteins and a longer (18S) rRNA molecule. The 
large bacterial subunit is composed of 5S and 23S rRNA and 34 proteins, which 
expanded to three species of rRNA (5S, 5.8S and 28S) and over 40 ribosomal proteins 
in eukaryotes (Lecompte et al., 2002). The core of the ribosome is very well conserved, 
though eukaryotic ribosomes have acquired expansion segments, insertions of often 









 Fig. 4. Structure of the 60S ribosomal subunit. A) Crystal structure of the S. 
cerevisiae 80S ribosome, viewed from the A site and large subunit side. Polypeptide 
exit tunnel, mRNA entry and exit tunnels are indicated. The large subunit is shown in 
yellow with orange proteins and the small subunit in cyan with blue proteins. 
Eukaryote expansion segments (ES) are shown in red (adapted from Jenner et al., 
2012).  B) Secondary Structure of 28S rRNA with domains outlined (adapted from 
Cannone et al. 2002). 
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The 18S rRNA of the small subunit coordinates tRNA binding and codon 
recognition, while the 28S rRNA of the 60S subunit catalyzes peptide bond formation. 
Transfer RNAs (tRNA) are key players involved with the ribosome and formation of 
peptides. They are 74-95 nucleotide long polynucleotides, folding into characteristic 
cloverleaf secondary structures.  Carrying an amino acid on their 3’ end, they provide the 
large subunit with substrates for peptide formation while their anticodon loop interacts 
with the small subunit and its bound mRNA to ensure incorporation of the correct 
building blocks.  Additional contacts to the ribosome are formed by the D and T-loops of 
tRNA (Agrawal et al., 2000).   
While both eukaryotic and prokaryotic ribosomes carry out the same function, 
they work in very different environments. In bacteria, translation proceeds co-
transcriptionally and because of the operon organization of prokaryotic genes, re-
initiation on one transcript occurs regularly. In contrast, transcription and translation 
occur in two separate cellular compartments in eukaryotes. Eukaryotic translation of 
mRNAs begins with initiation (Fig. 5). During the initiation phase, the 40S ribosomal 
subunit is associated with initiator tRNA, and associated initiation factors; this complex 
unites with mRNA bound to a separate group of initiation factors. The 60S large 
ribosomal subunit is later recruited to form an 80S ribosome, marking the end of initiation 
and the beginning of elongation (Jackson et al., 2010). Elongation begins with the 
delivery of aminoacyl-tRNA into the ribosomal A-site (aminoacyl), mediated by the 







This is followed by peptidyl transfer and the eEF2-mediated peptidyl-tRNA translocation 
from A-site to P-site (peptidyl-site) while deacyltated tRNA is simultaneously transferred 
from the P- to E-site (exit). The highly conserved peptidyl transferase center (PTC) 
resides in the 60S subunit of the ribosome and is the epicenter of peptide bond 
formation. In order for peptide bonds to form, aminoacyl-tRNA and peptidyl-tRNA must 
to be properly aligned in the A-site and P-site of the PTC (Merrick, 1992; Polacek and 
Mankin, 2005). 
 Fig. 5. A simplified overview of eukaryotic translation initiation. The eIF2-tRNA-
GTP ternary complex binds the small ribosomal subunit before recruitment of the 
mRNA message. After localization of the start codon to the ribosomal P-site and 
dissociation of the initiation factors, the large ribosomal subunit can bind and 














Fig. 6. The Eukaryotic Elongation Cycle. eEF1A delivers its acylated tRNA cargo 
into the A-site of the 80S ribosome. Upon codon recognition eEF1A hydrolyzes GTP 
and recycles, leaving the tRNA behind. The ribosome catalyzes peptidyl transfer, 
thereby attaching the nascent peptide to the A-site tRNA. eEF2 translocates the 
deacylated P-site tRNA into the E-site and the A-site tRNA into the P-site, thereby 
clearing the A-site for the next round of elongation (Adapted from Merrick 1992 and 
created by T. Schneider-Poetsch). 
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Regulation of protein translation plays an essential role in cell survival, especially 
in fast-proliferating cancer cells (Bhat et al., 2015). Inhibitors of eukaryotic protein 
synthesis, including the translation elongation inhibitor homoharringtonine, have entered 
the clinic, establishing translation as a promising target for chemotherapy (Gandhi et al., 
2014).  Not only is this promising for future cancer therapeutics; perturbation of 
translation by new small molecules will allow us to dissect minute molecular details of 
the process, providing valuable insight into the eukaryotic ribosome and its function. 
These insights will allow us to establish further contrasts between prokaryotic ribosomes, 
facilitating the development of new antibiotics. 
 
Results 
Inhibition of protein synthesis by Agelastatin A 
As an initial approach to elucidating the mechanism of the antitumor action of 
AglA, we began by investigating its cellular effects (Fig. 7A) using a phenotype-based 
approach, determining whether AglA has a specific effect on three major cellular 
processes: DNA replication, transcription, or translation. The effects of AglA on DNA 
synthesis, RNA synthesis, and global protein synthesis were determined using 
incorporation of [3H]-thymidine, [3H]-uridine, and [35S]-methionine and cysteine as 
readouts, respectively. Treatment of HeLa cells with AglA for 1 hour led to a dose-
dependent inhibition of incorporation of [3H]-thymidine with an IC50 of 0.39 µM, and of 
[35S]-methionine with an IC50 of 0.29 µM. In contrast, RNA synthesis as judged by 
incorporation of [3H]-uridine was not significantly affected (Fig. 7B). As a positive control, 
treatment with CHX led to inhibition of [3H]-thymidine with an IC50 of 0.059 µM, and [
35S]-
methionine with an IC50 of 0.045 µM (Fig. 7C). Both AglA and CHX inhibited DNA 
synthesis and translation, although CHX is ~6 fold more potent than AglA (Fig. 7D). As 
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observed in previous work with translation inhibitors differences in the observed IC50 
values between cell proliferation and translation assays may be attributed to the different 
drug incubation times and intrinsic sensitivity of the different assays (Dang et al., 2011; 






Fig. 7. Inhibition of protein synthesis by AglA. A).Chemical Structure of 
Agelastatin A B). Dose-dependent inhibition of translation by AglA. HeLa cells 







S]-cysteine/methionine for 1 hr. Protein 
synthesis was measured by scintillation counting of trichloroacetic acid (TCA)-
precipitated proteins on a filter. DNA synthesis and transcription were monitored 
by scintillation counting of nucleic acids bound to a filter. C). Mean values ± SEM 
(error bars) from 3 independent experiments are shown. IC50 values are listed ± 
SE. D). Drugs were added to a rabbit reticulocyte lysate (RRL) cocktail that 
included a control luciferase poly(A) mRNA (supplied by Promega) and [
35
S]-





To verify that AglA directly blocked translation, protein synthesis from luciferase 
mRNA templates in rabbit reticulocyte lysate (RRL) and [35S]-methionine was used. AglA 
also inhibited protein synthesis in a dose-dependent manner in the RRL system (Fig. 
7E). The lysate contains the cytosolic components necessary for protein synthesis, 
eliminating the possibility of downstream signaling effects on protein translation (Beckler 
et al., 1995).  
 
Agelastatin A inhibits translation elongation 
To distinguish between the possibilities of AglA interfering with the initiation or 
elongation phase of protein synthesis, a dual luciferase assay was conducted. Many 
viral mRNAs and a relatively small number of cellular mRNAs are translated through an 
internal ribosome entry site (IRES). HCV IRES-mediated translation initiation does not 
require the 5’ 7meG-cap structure. By recruiting initiation factors directly to the AUG start 
codon, HCV can bypass the eIF4F complex, which contains cap-binding factors eIF4E, 
and initiation factors eIF4A and eIF4G (Otto and Puglisi, 2004). The dual luciferase 
reporter assay uses bicistronic in vitro reporters with a conventional capped firefly 
luciferase, followed by renilla luciferase under the translational control of an HCV IRES 
element, which is resistant to inhibitors of translation initiation. Transcribed HCV IRES 
dual luciferase reporters were used to perform in vitro translation assays with RRL. AglA 
dose-dependently inhibited both cap-dependent and IRES-dependent translation of both 
luciferase reporters. As a control, CHX was found to inhibit both cap- and HCV IRES-
dependent translation. In contrast, Pateamine A (PatA), a translation initiation inhibitor, 
only inhibited cap-dependent translation (Fig. 8A). These results suggested that AglA’s 















Fig. 8. AglA inhibits translation elongation. A) Dual reporters with a 
conventional capped firefly luciferase followed by renilla luciferase under the 
translational control of HCV IRES were used in in vitro RRL translation assays in 
the presence of different concentrations of AglA , 4 µM PatA, and 4 μM CHX. B) 
Stress grandule induction performed in U2OS cells stably expressing GFP-G3BP 
in the presence of different compounds as indicated. Images (40x objective) were 





To further verify that AglA inhibited translation elongation rather than initiation, 
we determined its effect on stress granule formation in cells. Translation initiation 
inhibitors are known to trigger stress granule formation. In contrast, translation 
elongation inhibitors prevent the formation of stress granules (Dang et al., 2011). The 
induction of stress granules was performed in U2OS cells stably expressing GFP-G3BP, 
a stress-granule marker. Upon AglA treatment, no stress granule formation was 
observed, similar to results obtained in the presence of CHX (Fig. 8B). Arsenite, a known 
inducer of stress granules, was also used. As expected, pretreatment with CHX 
prevented stress granule formation induced by arsenite. Pretreatment with AglA also 
blocked stress granule formation in response to arsenite, albeit slightly less potently than 
CHX.  
 Translation elongation can be further subdivided into three major steps. First, 
aminoacyl-tRNA is delivered to the ribosomal A-site by eEF1A. Second, peptide bond 
formation occurs. Finally, eEF2 mediates peptidyl-tRNA translocation from A-site to P-
site, and deacylated-tRNA is transferred from the P to E-site. Using a reconstituted 
system consisting of ribosomes, a poly (U) template, eEF1A, GTP, and aminoacyl-tRNA, 
we assayed the effects of AglA on dipeptide bond formation, and the products of the 
reaction were separated using an electrophoretic cellulose thin-layer chromatography 













Fig. 9. Effects of AglA on translation peptidyl transfer. A). AglA decreased the 
rate of dipeptide formation. Radiolabeled methionine with initiation complexes 
mixed with drug and pre-incubated for 5min. eEF1A, tRNA-Phenylalanine, and 
GTP were mixed with complexes and incubated at given time points. Aliquots 
were quenched in 250mM KOH then run on TLC plates for analysis of dipeptides. 
B,C). AglA does not inhibit eEF1A’s ribosome-dependent GTPase activity. Yeast 
eEF1A, phenylalanyl tRNA-Phe and 80S ribosomes were incubated in 1X buffer E 
with α-32P GTP, and aliquots were quenched at the indicated timepoints. TLC 





We next assessed whether AglA could affect the GTPase activity of eEF1A. GTP 
hydrolysis by eEF1A is highly dependent on both ribosomes and aa-tRNA (Fig. 9B). In 
the presence of these factors, AglA had no effect on the rate of GTP hydrolysis (Fig. 
9C), suggesting that eEF1A-mediated tRNA loading is not affected and ruling out eEF1A 









Fig. 10. AglA does not alter elongation factor distribution. A). Lysates of 
treated 293T cells were separated by density centrifugation and fractionated. 
Each fraction’s RNA concentration was measured by absorbance B). Each 
fraction’s elongation factor and ribosomal content was observed by immuno-
blotting. S6 denotes ribosomal protein rps6.   
67 
 
As further support of the conclusion that eIF1A is not a target of AglA, the 
association of eEF1A across a sucrose gradient was observed. Several known 
translation inhibitors, such as didemnin B, exert their effect by arresting eEF1A on the 
ribosome(Ahuja et al., 2000; Gomez-Lorenzo, 2000). Should AglA have a similar effect, 
then one would expect a change in its distribution on a density gradient. 293T cells were 
treated with inhibitors and their lysates were centrifuged across sucrose density 
gradients. Fractions were collected by hand and the optical density of each fraction was 
determined. Aliquots were run on polyacrylamide gels and transferred onto nitrocellulose 
membranes.  Each membrane was probed against eEF1A, eEF2 and the small 
ribosomal subunit protein S6, which served as an indicator of ribosome content. No clear 
change in eEF1A or eEF2 was observed in the presence of AglA (Fig 10). If AglA had 
caused tighter association of ribosomes and elongation factors, one would have 
expected either factor to concentrate in the 80S fraction. If eEF1A had bound more 
strongly, eEF2 should have associated less because the binding sites for both 
elongation factors overlap at the ribosomal A- site. 
 
Footprinting analysis reveals binding site of Agelastatin A 
Based on AglA’s strong effect on the accumulation of dipeptides, we 
hypothesized that binding was occurring near the peptidyl transferase center. We 
performed molecular docking to assess the potential binding site and binding mode of 
AglA in the yeast ribosomal peptidyl transferase center (PTC). According to the docking 
model, AglA docks well into the PTC (Fig. 11A). The pyrrole ring of AglA was predicted 
to form a π–π stacking with C2821 and A2820 of the yeast 25S rRNA. In order to 
validate this model and confirm the binding site of AglA on the ribosome, we performed a 
whole-ribosome dimethyl sulfate (DMS) protection assay with a modified form of DMS-
seq (Ding et al., 2013; Rouskin et al., 2013). Purified yeast ribosomes were pre-
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incubated with AglA, and probed with 90 mM DMS, which methylates adenine and 
cytosine residues. Instead of the classic method of looking for reverse transcriptase (RT) 
stops by gel (Moazed et al., 1986) or sequencing (Ding et al., 2013; Rouskin et al., 
2013), we used a thermostable group II intron RT(Siegfried et al., 2014) which proceeds 
past DMS-modified nucleotides, but incorporates mismatches at these methylated 
positions at high frequency. Counting these mismatches by high-throughput sequencing 
produces a quantitative readout (Siegfried et al., 2014) of the extent of DMS 
modification.  
Treatment of ribosomes with cycloheximide (CHX) produced dose-dependent 
protection exclusively at 25S rRNA nucleotide C2764, where CHX was previously shown 
to bind (Garreau de Loubresse et al., 2014; Schneider-Poetsch et al., 2010) (Fig. 12A, 
12B ). Treatment with 0.5 mM or 1.0 mM AglA produced strong (~30-fold) and specific 
protection at the PTC nucleotide 25S C2821 (Fig. 11B, 11C), consistent with 
computational modeling. The neighboring nucleotides, A2820, A2941, and C2942 were 
also protected by AglA treatment, but to a lesser extent (Fig. 11D). However, the level of 
modification at these nucleotides was lower than for C2821 in the absence of AglA. 
A2820 specifically showed about 2-fold reduction in DMS signal upon AglA treatment; 
however, the signal is ~25 fold lower than for C2821. Thus, it did not pass cutoffs for 
statistical significance in our assay. 
 
Crystal Structure of 80S/Agelastatin A complex 
In collaboration with Dr. Marat Yusupov, we determined the X-ray crystal 
structure of AglA bound to the yeast ribosome. AglA binds to the PTC and precisely at 
the A-site on the large ribosomal subunit (LSU). Upon binding of AglA, the residue U-
2875 of the 80S ribosome undergoes a major rearrangement and it flips up compared to 
what is seen in the structure of vacant 80S ribosome (Ben-Shem et al., 2011) (Fig. 13). 
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Additionally, the inhibitor induces the displacement of A-2819, A-2820, and C-2821 in 
order to create stable contacts with the LSU A-site pocket, through the formation of 
stacking interactions. Moreover, the flipping-up of uracil 2875 induces the displacement 
of A-2404, probably due to steric hindrance between these two residues. AglA forms two 
additional hydrogen bonds with the rRNA surrounding the A-site and, more specifically, 
with U-2869 and U-2873. Such rearrangements are common for inhibitors binding. LSU 
A-site pocket, and show how natural compounds can develop to accommodate in the 
eukaryotic ribosome. Similarly to this, the base of rRNA C-2821 flips out compared to the 
vacant 80S structure, establishing an additional bond with an Mg2+ ion; this agrees with 
the large accessibility change in the footprint data. Finally, the essential bromide group 
of AglA forms a π-stacking interaction with U-2875, a quite unusual feature for inhibitors 















Fig. 11. AglA is bound within the PTC of the larger ribosomal subunit. A). 
Molecular docking model of the interaction of AglA with the Saccharomyces 
cerevisiae ribosome (PDBID: 4U52). The numberings correspond to the 25S 
yeast ribosome sequence. B,C). MA plots showing, for each rRNA nucleotide, the 
average DMS-dependent mutation rate on the x axis, against the fold change 
upon AglA treatment on the y axis. Nucleotides passing significance and fold-
change cutoffs are orange, and changing nucleotides from panel C are labeled. 
D). Fold change in mutation rate, relative to a no-DMS control, for an unaffected 













Figure 13. Crystal structure of A-site bound AglA.  A) AglA (pink) fitted in the 
difference map (mFO-DFc). Structure has been determined to the resolution of 
3.5 Å. See table 5 for statistics of data collection and processing. B) AglA (pink) 
forms hydrogen bonds with U2869 and U2873 and π-stacking interaction with 
U2875 of 25S rRNA (green) and electrostatic interaction with a magnesium ion 
(yellow). C) Stacking interactions between A2819, A2820, and C2821 of 25S 
rRNA (green) at A-site and AglA (pink). D) superposition of vacant ribosome 
structure (orange; PDB code: 4V88) and ribosome bound to AglA structure 
(green) displaying major movements of nucleotides A2404, C2821, and  U2875 
















Table 5. Data collection and refinement statistics of ribosome bound AglA 





Although AglA has been an attractive natural product for biological studies for the 
past two decades since its first isolation, its underlying cause of antiproliferative effects 
in cells and molecular target(s) have remained a mystery. In this study, we identified the 
ribosomal peptidyl transferase center as the key target of AglA.  It has previously been 
reported that AglA down-regulates β-catenin expression, causing repression of OPN and 
inhibition of OPN-mediated malignant cell migration (Mason et al., 2008). We surmise 
that this is most likely due to AglA causing reduced levels of the protein to be translated 
















Fig. 14: Inhibition of DNA replication by aphidicoline. HeLa cells were 
incubated with varying concentrations of each compound in the presence of either 
[3H]-thymidine,  [3H]-uridine, or [35S]-cysteine/methionine for 1 hr. Protein 
synthesis was measured by scintillation counting of trichloroacetic acid (TCA)-
precipitated proteins on a filter. DNA synthesis and transcription were monitored 




AglA inhibited both protein synthesis and DNA replication in HeLa cells. As a 
comparison, we also tested the incorporation of [3H]-thymidine, [3H]-uridine, and [35S]-
methionine and cysteine  in the presence of aphidicolin, an inhibitor of DNA polymerase 
α (Oguro et al., 1979; Spadari et al., 1982). Only DNA replication was inhibited (Figure 
14).  Interestingly, CHX similarly affects both protein synthesis and DNA replication, and 
the same phenomenon has been reported for a number of other translation inhibitors 
(Chan, 2004). It is possible that this is the result of a primary effect on the synthesis of 
fast-turnover proteins necessary for DNA replication, suggesting the existence of a 
mechanism directly coupling DNA replication and translation (Abid et al., 1999; Berthon 
et al., 2009).  
Three independent pieces of evidence allowed us to rule out the possibility that 
AglA was inhibiting translation initiation. First, AglA inhibited both cap-dependent and 
initiation factor-independent HCV IRES reporter translation. Second, AglA does not 
induce stress granule formation in cells. Finally, because the eukaryotic ribosome’s 
highly conserved nature, we were able to take advantage of a yeast system to further 
dissect the mechanism of AglA. Initially, we tested the effects of AglA on yeast culture 
growth; however, there was no strong effect (Fig. 15). This may be attributed to AglA’s 
inability to penetrate the yeast cell wall. Fortunately, in an in vitro semi purified system, 
AglA strongly inhibited dipeptide bond formation, suggesting that AglA was either 
inhibiting eEF1A, or directly binding within the ribosome itself. AglA caused no effect on 
eEF1A-dependent GTP hydrolysis, suggesting to us that peptide bond formation itself 









Molecular docking predicted that AglA could bind within the peptidyl transferase 
center of the ribosome, with the pyrrole ring predicted to form a pi-pi stacking with C2821 




Fig. 15. Effect of AglA on the growth of Saccharomyces cerevisiae. AglA and 
rapamycin were added at 10 µM each.  
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Fig. 16. tRNA binding sites. Thermus thermophilus tRNAs aligned onto the 
yeast structure59. tRNAs are positioned in the E/P/A sites from the left: A2820, 











We were extremely surprised to find how closely the molecular docking model 
predicted the binding site of AglA, which was validated by both the DMS-Seq footprint 
and crystal structure. These findings provide a potential clue for future analogs with 
improved potency; consistent with our predication, previously reported SAR studies 
(Jouanneau et al., 2016) show a gradual loss in activity as the size of the C14 
substituent increases, as larger substituents at this position may bump into A2820 that 
forms π–π interaction with AglA. The PTC of the ribosome was also found to be the 
binding site of several other translation inhibitors, including anisomycin, which has been 
reported to form a hydrogen bond with C2821, thus allowing protection from chemical 
modification at this position (Garreau de Loubresse et al., 2014; Rodriguez-Fonseca et 
al., 1995). Although they occupy a similar binding pocket in the PTC, the structures of 
these compounds are quite distinct (Fig. 17) and show a distinct interaction pattern with 
nearby nucleotides. Flipping of residues C-2821, U-2875 and A-2404 seems to be 
dependent on the chemical structure of the inhibitor rather than the accommodation of 
the inhibitor itself, as shown in our comparison with narciclasine (NAR) and ANI (Fig. 
18). In the case of NAR, for instance, U-2875 adopts a conformation close to the vacant 
80S while ANI causes this residue to flip up in a manner similar to the AglA structure. A-
2404, by contrast, is very mobile and rearranges in different positions when comparing 












Fig.17. Chemical structures of current eukaryotic translation inhibitors that 



























Fig.18. Structural comparison of AglA and other A-site inhibitors. A) 
Superposition of ribosome bound to anisomycin (ANI) structure (blue; PDB code: 
4U3M) and ribosome bound to AglA structure (green) displaying differences in 
movements of nucleotides A2404, C2821, U2875 (black arrows) induced upon 
binding of ANI (cyan) or AglA (pink) to A-site. B) Superposition of ribosome bound 
to narciclasine (NAR) structure (yellow; PDB code: 4U51) and ribosome bound to 
AglA structure (green) displaying differences in movements of nucleotides A2404, 
C2821, U2875 (black arrows) induced upon binding of NAR (orange) or AglA 
(pink) to A-site. C) Superimposition of ribosome bound to NAR  structure (yellow; 
PDB code: 4U51), ribosome bound to ANI structure (blue; PDB code: 4U3M) and 
ribosome bound to AglA structure (green) displaying differences in movements of 
nucleotides A2404, C2821, U2875 (black arrows) induced upon binding of NAR 
(orange) or ANI (cyan) or AglA (pink) to A-site. D) Binding pocket of AglA (pink), 
ANI (cyan; PDB code: 4U3M) and NAR (orange; PDB code: 4U51) in vacant 
ribosome structure (grey; PDB code: 4V88). Nucleotides pointed by black arrows 





Among the compounds identified as inhibitors of peptide bond formation, 
Homoharringtonine was approved in 2012 for use as a treatment for patients 
with chronic myeloid leukemia who are resistant to tyrosine kinase inhibitors such as 
imatinib (Moen et al., 2007). These recent developments strongly highlight the need for 
further evaluation of translation inhibitors for use against cancers. In particular, AglA and 
its analogues have displayed admirable blood-brain barrier penetration and potent 
activity against CNS related tumors in murine models, making it an excellent candidate 
for brain cancer studies.  
Naturally, translation inhibitors will always remain generally toxic due to the 
requirement of protein turnover in fast growing cells. However, quickly proliferating cells 
such as aggressively growing tumors should suffer more strongly from translation 
inhibition compared to normal somatic cells. Besides their overall antiproliferative effects, 
translation inhibitors may also prevent the cell from producing anti-apoptotic proteins, 
which could aid the development of resistance against other chemotherapeutic agents. 
In combination with a proven first-line chemotherapeutic, translation inhibition may act 
synergistically to enhance the primary drug’s effect and prevent the development of 








Materials and Methods 
Reagents and cell lines 
AglA was synthesized as reported (Reyes and Romo, 2012) and dissolved in 
DMSO. CHX, and GMPNP were purchased from Sigma. HEK293T and HeLa cells were 
cultured in DMEM medium supplemented with 10% FBS and were maintained in a 5% 
CO2 atmosphere.  
 
Metabolic labeling 
HeLa cells were used for cellular metabolic labeling experiments. HeLa cells 
(20,000 per well) were seeded in 96-well plates. Twenty four hours after seeding, drugs 
were added at the indicated concentrations, followed by addition of an aliquot of 1 µCi of 
[3H]-uridine or [35S]-methionine (Perkin Elmer) for 1 h. Cells were washed twice with 200 
µl of cold PBS and lysed by addition of 100 µl lysis buffer [20 mM Tris-HCl, pH 7.4, 1% 
SDS, 100 µg/ml yeast tRNA (for [3H]-uridine incorporation) or 25 mM Tris-HCl, pH 7.6, 
150 mM NaCl, 1% NP-40, 1% deoxycholate, 0.1% SDS, 100 µg/ml BSA (for [ 35S]-
methionine incorporation)]. After a 20-minute incubation at 4 °C, 100 µl of 20% 
trichloroacetic acid (TCA) was added and the resulting mixtures were transferred to 
Millipore MSFCN6B10 filter plates. After 2 hours incubation at 4 °C, the mixtures were 
filtered under vacuum, and the plates were washed twice with 100 µl 5% TCA and twice 
with 100 µl ethanol. The plates were dried overnight, and 50 µl of Optiphase Supermix 
was added to each well and incorporation of 3 H or 35S was quantified by scintillation 








Dual luciferase reporter assay 
HCV IRES dual luciferase reporter vector was linearized with BamHI (NEB) and 
transcribed using T7 polymerase (Promega). Reactions were carried out as previously 
described (Dang et al., 2011), using the Dual-Luciferase reporter assay system 
(Promega). 
 
Induction of stress granules 
U2OS cells stably expressing GFP-G3BP were treated with the indicated 
compounds for 1 hour. Cells were pretreated with either CHX or AglA for 30 minutes 
before arsenite addition for 1 hour. Cells were then fixed with 4% paraformaldehyde for 
10 minutes, and washed twice with PBS. Images were captured using an Olympus B 
X61 fluorescence microscope, equipped with a Roper Photometrics CoolSnap HQ CCD 
camera.  
 
Elongation factor distribution 
Fifteen centimeter culture dishes of human embryonic kidney (HEK) 293T cells 
were grown to confluency. Drugs were added at the indicated concentrations and 
incubated with the cells for 30 min. Cells were lyzed in 0.5 ml 30 mM Tris-HCl, pH 7.4, 
100 mM KCl, 5 mM MgCl2, 2 mM DTT, and 1% Triton-X 100. After clearing the lysate of 
debris by centrifugation at 13,000 rpm, 4˚C for 10 min, aliquots containing the same 
amount of RNA (measured by OD254) were loaded onto linear 15-45% sucrose density 
gradients in 20 mM Hepes-KOH, pH 7.4, 100 mM KCl, 5 mM MgCl2 and 2 mM DTT. 
Gradients were fractionated in 500 µl aliquots by hand. The optical density at 254 nm 
was determined for each fraction. Aliquots of each fraction were boiled with 2x SDS 
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loading buffer and run on 10% SDS-PAGE gels. Protein was transferred onto 
nitrocellulose membranes at 4 ˚C and 20 V overnight or at 90 V for 2 h. Membranes 
were blocked for at least one hour in 5% milk in TBS-T (50 mM Tris-HCl, pH 7.0, 150 
mM NaCl, and 0.5% Tween-20) buffer and then probed with primary antibodies against 
ribosomal proteins or elongation factors for 3 h to overnight at 1:500-1:1000 dilution. 
Membranes were washed 3 times with TBS-T buffer before application of secondary 
antibody in 5% milk at 1:2000 dilution, followed by 3 washes with buffer and addition of 2 
ml of horseradish-peroxidase substrate per membrane. Luminescence was detected on 
a Kodak Image Station 440 camera system. 
 
In vitro peptidyl transfer assays 
Ribosome initiation complexes were assembled and purified as previously 
described (Eyler and Green, 2011), containing Met-tRNAIMT in the P site and a phe 
codon (UUC) in the A site. The open reading frame of the mRNA used was Met-Phe-
Stop (AUG-UUC-UAA). For peptidyl transfer, Phe-tRNAPhe ternary complex was 
prepared by mixing 1µM Phe-tRNAPhe, 2uM eEF1A and 1mM GTP in buffer E (20 mM 
Tris-Cl, pH 7.5, 100 mM potassium acetate, 2.5 mM magnesium acetate, 0.25 mM 
spermidine, 2 mM DTT) at 26 °C for 15 min. During this time, initiation complexes (20 
nM) were incubated with either drug or DMSO for 5 minutes at 26 °C. Ternary complex 
was then added to each initiation complex: drug mixture to initiate the reaction. Time 
points were taken after 10, 60, and 120 seconds and quenched in 250 mM KOH. 
Samples were run on electrophoretic TLCs (Millipore) at 1200V for 24min, developed 
using a Typhoon FLA 9500 Phosphorimager system, and quantified using 





Yeast growth assay 
WT yeast cultures were grown in yeast peptone dextrose (YPD) medium. 
Saturated starter cultures were diluted to 0.05 OD600 units and plated at 1 ml each into 
24 well plates. Increasing concentrations of AglA were added in triplicate and the cells 
were incubated at 30 ˚C for 6 hours to monitor initial log phase growth. 
 
eEF1A GTPase assay 
S. cerevisiae ribosomes (Acker et al., 2007) and eEF1A (Eyler and Green, 2011) 
were purified as previously described. Yeast phenylalanine tRNA (chemblock) was 
charged by incubation with phenylalanine and S. cerevisiae S100 extract (Eyler and 
Green, 2011), and recovered by phenol extraction and ethanol precipitation. eEF1A 
GTPase assays were assembled in 10μl reactions containing 1x buffer E by addition, in 
order, of S. cerevisiae eEF1A (0.25μM), charged phenylalanine tRNA (Eyler and Green, 
2011) (0.25μM), 40S ribosomal subunits(0.20μM), 60S ribosomal subunits(0.20μM) and 
0.5ul AglA in DMSO. Reactions were started by addition of α-32P GTP (Perkin Elmer) to 
0.133μM.From each reaction, 1.5μl aliquots were quenched in an equal volume of 60% 
formic acid at the indicated time points. GTP and GDP were separated on PEI cellulose 
F TLC plates (Millipore) with 0.5M KH2PO4 pH 3.5. The dried plates were developed 
using a Typhoon 9410 phosphorimager system (GE Healthcare Life Sciences) and 
quantified using ImageQuantTL (GE Healthcare Life Sciences). 
 
Computational Modeling 
The receptor model used for molecular docking was derived from the crystal 
structure of yeast 80s ribosome bound to a small molecular inhibitor Nagilactone C 
(PDBID: 4U52). Because the  whole 80s ribosome structure is too large for the docking 
study, the nucleotides and amino acids that were 10Å away from the ribosomal peptidyl 
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transferase center (PTC) were deleted. Water molecules, ions and nagilactone C were 
also removed. After the addition of hydrogen atoms and charges, a brief relaxation of the 
receptor structure was performed by using the Protein Preparation module in Maestro 
v7.5 (Schrödinger Inc. NY). LigPrep module in Maestro v7.5 (Schrödinger Inc. NY) was 
used to prepare the 3D structure of AglA. Afterwards, AglA was docked into the PTC by 
using Glide v4.0 (Schrödinger Inc. NY) in the extra-precision (XP) mode. Finally, the 
predicted binding mode between AglA and yeast 80s ribosome PTC were visualized and 
analyzed in Pymol 0.99rc (www.pymol.org). 
 
DMS modification 
DMS treatment was performed in a final volume of 25ul, containing 30mM K-
HEPES (pH 7.5), 3mM MgOAc2, 100mM KCl, 2mM DTT, 0.5μM each of 40S and 60S 
yeast ribosomal subunits.  For AglA treatment, 10% of AglA in DMSO was added. For 
CHX treatment, a 10% volume of CHX in water was added. Reactions were brought to 
24μl, and pre-incubated at 26°C for 5 minutes.  1μl of 2.25M dimethyl sulfate (sigma 
D186309, use within 6 months) diluted in ethanol (to 90mM final concentration) was 
added, reactions mixed by pipetting, and incubated at 26°C for 8 minutes. Reactions 
were quenched by addition of 475μl of (30% 2-mercaptoethanol, 0.3M sodium acetate, 
pH 5.5). Reactions were isopropanol precipitated, resuspended in 200μl of 0.3M sodium 
acetate, pH 5.2 and extracted twice with acid phenol-chloroform-isoamyl alcohol 
(thermo-fisher AM9722). Reactions were ethanol precipitated with 10ug glycogen, 
washed with 80% ethanol, resuspended in 40μl water, and RNA concentrations 







4μg of RNA was fragmented by incubation at 95°C for 5 minutes with 10mM 
ZnCl2, quenched by addition of EDTA to 20mM on ice. RNA was precipitated and 3’ 
ends were dephosphorylated by incubating in 12.5μl reactions of 1x PNK buffer (NEB), 
1.25ul T4 PNK (NEB) and 0.5ul SUPERase-In (Thermo-Fisher) at 37°C for 1 hour. 
Reactions were run on a 10% TBE-Urea PAGE gel (Bio-Rad), alongside 10bp DNA 
ladder (Invitrogen) and a slice was cut from the gel between the 60 and 70bp markers. 
From this point, the library preparation proceeded essentially as previously described 
(Rouskin et al., 2013) with the following modifications. For linker ligation, 10 picomoles of 
pre-adenylated miRNA cloning liker 2 was used, [IDT , 
AppCACTCGGGCACCAAGGA/3ddC/, pre-adenylated in-house based on (Pfeffer et al., 
2005) for its higher annealing temperature. 10μl Reverse transcription (RT) reactions 
were performed with half of the gel-purified ligated product, 1x first stand buffer 
(Invitrogen), 0.5mM dNTPs, 0.5μl SUPERase-In (Thermo-Fisher) 100nM of 
complementary circularizeable RT primer (IDT, 
/5Phos/AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGC/i
SP18/CACTCA/iSp18/TTCAGACGTGTGCTCTTCCGATCTGTCCTTGGTGCCCGAGTG
), 5mM DTT and 0.5μM TGIRTIII RT (InGex) for 1 hour at 60°C. Instead of truncated RT 
products, full-length RT products were gel-purified. Circularized cDNA was prepared for 
Illumina sequencing with 11-13 cycles of PCR with forward primer (IDT, 
AATGATACGGCGACCACCGAGATCTACAC) and barcoded reverse primer 
(IDT,CAAGCAGAAGACGGCATACGAGATxxxxxxGTGACTGGAGTTCAGACGTGTGCT
CTTCC, where xxxxxx was one of 24 base-balanced barcodes). Data generated by 
these experiments is deposited in Gene Expression Omnibus 
(Gene accession GSE85619.  Full-length libraries were gel-purified from a 10% TBE-
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PAGE gel (Bio-Rad) quantified by bioanalyzer (Agilent), pooled, and sequenced on an 
Illumina HiSeq 2000 in 100nt single-end rapid mode. 
 
Sequencing data analysis 
The linker sequence for all reads was trimmed using cutadapt (Martin, 2011), and 
the 5’-most 3 nucleotides were removed with FASTX trimmer. Any reads without an 
identifiable 3’ linker sequence were discarded. The trimmed reads were fed into the 
ShapeMapper package (Siegfried et al., 2014) to further trim the reads based on quality, 
and to count mismatches relative to the yeast rDNA sequence (from the UCSC genome 
browser, August 29th, 2011 version). The mutation rate was defined as the ratio of the 
number of sequence mismatches at an rRNA position, divided by the total number of 
trimmed reads overlapping a position. The error at a position was defined by the Poisson 
sampling error as previously described (Siegfried et al., 2014). Several rRNA nucleotides 
have in vivo methylations on their Watson-Crick face (18S 1191; 25S 
645,2142,2634,2843), and reproducibly have up to 50-90% mutation rates, even in the 
absence of DMS treatment. These nucleotides demonstrate the quantitative nature of 
the mismatches introduced by the RT, but are excluded from downstream analysis. 
Log10 fold changes in DMS-induced mutations between treatment and control were 
computed, and the errors for the two datasets were propagated through the division and 
log transformation. To determine if any of these changes constituted significant 
protections or deprotections, z scores were computed from these means and standard 
errors, based on a distribution with a mean of 0, the normal distribution integrated from 
the z score to positive or negative infinity, and tested against a p-value of 0.01, with 
bonferroni correction. A 3-fold change cutoff was also instituted, based on analysis of 
cycloheximide titrations. The analysis software, which produces quality control 
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information, wig files, output tables, and plots from FASTQ files is freely available at 
https://github.com/borisz264/mod_seq/.  
 
Ribosome purification, complex formation, crystallization and crystal treatment 
80S ribosomes from the yeast S. cerevisiae were purified and crystals were 
prepared as described previously(Ben-Shem et al., 2011; Garreau de Loubresse et al., 
2014). Crystals were grown at 4°C by hanging-drop vapor diffusion and then treated 
based on the previously described protocol(Ben-Shem et al., 2011; Garreau de 
Loubresse et al., 2014) maintaining an increased glycerol concentration to 20% in all 
intermediate solutions. AglA was added at a final concentration of 250 μM in the last 
treatment solution, where crystals of the 80S ribosome were finally soaked in for 60 
minutes prior to freezing in liquid N2.  
 
Data collection, processing and structure determination 
Data of the 80S/AglA complex have been collected at the X06SA beamline at the 
PSI-SLS (Switzerland) and at the PROXIMA-1 beamline at SOLEIL (France), finally 
yielding a complete dataset at maximal resolution of 3.5 Å (Table 5). Data were 
processed using XDS and scaled with XSCALE 73. The resulting file was converted into 
mtz format with the XDSCONV tool and then submitted for a first cycle of rigid-body 
refinement in phenix.refine (PHENIX suite(Adams et al., 2010)) using, as initial model, 
the Saccharomyces cerevisiae vacant 80S ribosome (PDB code: 4V88). Inspection of 
the resulting map allowed to detect positive difference density (Fobs – Fcalc) close to the 
A-site peptidyl-transferase center (PTC) and to place the AglA into it. Drawing of the 
chemical structure of AglA was performed using MarvinSketch suite (ChemAxon, 
http://www.chemaxon.com/), which resulted in the 3D coordinates of the compound. 
Dictionary of restraints for the AglA was generated by submitting the 3D coordinates to 
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the GradeWebServer (http://grade.globalphasing.org). Iterative model building and 
refinement were performed using Coot (Emsley and Cowtan, 2004) and phenix.refine 
respectively. A protocol of positional, grouped isotropic B-factor and TLS refinement 
using a strong weight for geometry restraints yielded the final statistics presented in 
Table 1. Structure validation was performed using Molprobity (Chen et al., 2010). 
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Coursera Online Certification, Sept 16 2016-Oct 2016, Design and Interpretation of 
Clinical Trials by Janet Holbrook, Ph.D., MPH and Lea Drye, Ph.D., Johns Hopkins University 
 
UNCF Merck Summer Intern, Jun 2010-Aug 2010 and Jun 2009-Aug 2009, Research 
Advisor: Rene Bartz, Ph.D., Merck Research Labs, RNA Therapeutics Department, West Point, 
PA 
 
UMBC Student Events Board President, Apr 2009-Apr 2010, Event Programmer, Apr 
2007-Apr 2009, University of Maryland, Baltimore County 
 
Research Assistant, Aug 2008-May 2010, Research Advisor: Dr. Charles Bieberich, 
University of Maryland, Baltimore County 
 
Summer Intern, May 2008-Aug 2008, Research Advisor: Dr. Richard Bodnar, Summer 
Undergraduate Research Program, University of Pittsburgh 
 
Summer Intern, Jun 2007- Aug 2007, Research Advisor: Dr. Nancy Colburn, NIH 
Summer Internship Program, National Cancer Institute, Frederick, MD 
 
Scholarships and Fellowship Awards 
F31 Predoctoral National Research Service Grant Award Recipient, 5F31AT008324-
02/AT/NCCIH, 2014-2016 
 
UNCF/Merck Science Initiative Undergraduate Fellow; 2009-2010 
 
UMBC Meyerhoff Scholar; 2006-2010 
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Honors and Activities 
 
Regulatory Affairs Professionals Society; 2015-present 
 
Judge, Annual Biomedical Conference for Minority Students; 2015 
 
American Society for Cell Biology Member; 2014 
 
Biomedical Careers Initiative; 2014-2015 
 
Hopkins Biotech Network; 2013-2015 
 
AAAS/Science Program for Excellence in Science Member; 2013 
 
UMBC Chapter of Young Alumni; 2011-2014 
 
Incentive Mentoring Program; 2011-2014 
 
VP of Events, Johns Hopkins Biomedical Scholars Association; 2010-2011 
 
 
 
 
 
 
 
 
  
